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Abstract 
 
Dementia, a term used to describe a clinical syndrome caused by 
neurodegeneration, is characterised by the progressive deterioration of an 
individual’s cognitive function and the development of behavioural abnormalities 
that affect memory, intellect and/or capacity for independent living. The worldwide 
prevalence of dementia is increasing due to population ageing and the number of 
individuals living with dementia has been expected to exceed 115 million by the year 
2050. Therefore, identifying risk factors, primary and secondary prevention 
strategies are global health priorities.  
 
Late-onset Alzheimer’s disease (AD) and vascular dementia (VaD) are 
considered the two most common forms of age-related dementia. Over the past few 
decades, the majority of AD-biomedical research has primarily focused on 
considering the putative causal association of brain parenchymal proteinaceous 
deposits with disease onset and progression. However, accumulating evidence has 
implicated a vascular origin for AD. Cerebral capillary dysfunction and 
neurovascular inflammation may be one of the earliest indicators of AD onset, 
preceding amyloidosis and neurodegeneration. Pathological dysfunction of cerebral 
capillary integrity has been demonstrated to coincide with the progressive decline in 
cognitive function and indeed, extensive capillary damage has been reported in brain 
regions specifically involved in cognition. Consistent with a causal role, 
experimental and clinical studies have shown therapeutic benefit in AD progression 
if cerebrovascular disturbances are corrected or attenuated.  
 
Epidemiological, clinical and animal model studies show that nutritional 
status is relevant to risk for AD/VaD and cognitive decline. A vascular axis is 
commonly purported to be central to nutritional mediators of central nervous system 
integrity. Vitamin D (VD) has generated considerable interest in the dementia field 
based principally on its supposed beneficial extra-skeletal roles in the brain and on 
cognitive performance. A number of experimental studies have demonstrated 
beneficial effects of VD, typically in the context of correcting for VD deficiency. 
However, paradoxical observations have been reported. Emerging evidence suggests 
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that higher VD concentrations may be associated with cerebrovascular and global 
cognitive abnormalities and interestingly, hypervitaminosis D has been causally 
related with a premature ageing phenotype in genetically modified mice. The anti-
oxidant and immunomodulatory effects of VD have been considered in the context of 
CNS function and cognition, however the effects of VD on cerebral capillary 
endothelium have not been previously considered.  
 
The complexity of the VD homeostatic system involves the regulatory effects 
of active calcium metabolites (ionised calcium, iCa) and parathyroid hormone 
(PTH). Indeed, aberrations in iCa and PTH homeostasis are both indicated in risk for 
several neurodegenerative disorders including AD/VaD. The interactive effects of 
the VD/iCa/PTH have not been considered in the context of cerebrovascular integrity 
and cognitive function.  
 
This thesis explores the novel hypothesis ‘The Vitamin D - Calcium - 
Parathyroid Hormone endocrine axis regulates cerebral capillary integrity and is 
associated with neurocognitive performance’. The hypothesis is further supported by 
an in-depth review of the literature presented in Chapter 1.  The main objectives of 
this thesis were to investigate the interactive and/or independent effects of 
hypervitaminosis D, iCa and PTH on the modulation of cerebral capillary integrity 
and function in genetically un-manipulated rodent models, presented in Publication 
1. The second primary objective of this thesis was to explore the potential association 
between VD, iCa and PTH homeostasis with neurocognitive function, as shown in 
Publication 2. 
 
To explore the putative regulatory and integrative effects of exogenous VD, 
iCa and PTH, on the function of cerebral capillary endothelium and neurovascular 
inflammation, clinically relevant states of dietary-induced hypervitaminosis D, 
endocrine mediated hypo - and - hyper - parathyroidism were modeled in two 
genetically un-manipulated rodent models for a duration of either 6, 12 or 24 weeks 
(Publication 1). Parenchymal extravasation of plasma-derived immunoglobulin G 
(IgG) was used as a surrogate marker of blood-to-brain cerebral capillary 
permeability and neuro-inflammation was determined by quantification of glial 
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fibrillary acidic protein (GFAP), representative of astroglial activation. Substantial 
cerebral capillary disturbances were demonstrated in the cerebral cortex and 
hippocampal formation in two rodent species in association with the dosage of VD 
supplement provided. Greater doses of VD were also associated with increased 
serum iCa and reduction in serum PTH. A dose response was suggested and 
parenchymal effects persisted for up to 24 weeks of the dietary intervention. 
Conversely, the provision of exogenous PTH did not increase cerebral capillary 
permeability despite a substantial increase in serum iCa concentration. Greater 
capillary permeability was observed in hypoparathyroid animals subjected to 
parathyroid gland ablation, concomitant with a reduction in serum iCa. Both VD 
supplemented and parathyroidectomised intervention groups showed modest 
increases in astroglial activation, whereas the provision of exogenous PTH reduced 
GFAP-expression. The overall findings from this study demonstrate that the 
provision of exogenous VD at levels that markedly suppress serum PTH and increase 
serum iCa can be detrimental and significantly compromise the barrier properties of 
cerebral capillary vessels but do not promote neurovascular inflammation per se. 
Moreover, the data from this study suggests PTH may have vasculo-protective 
effects and reiterates the importance of considering the synergistic and/or 
independent effects of metabolites and hormones related to VD homeostasis in the 
investigation of vascular-neurodegenerative conditions.  
 
Serum VD homeostasis was considered in context of neurocognitive 
performance in healthy, middle-aged and older aged adults; presented in Publication 
2. Based on the principle findings of Publication 1, iCa and PTH, critical regulators 
of VD homeostasis, were taken into consideration when exploring the putative 
effects of VD on cognitive performance. A cross-sectional sample cohort of 181 
individuals (116 female; 65 male) between the ages of 43 to 84 years of age was 
included in the sample analysis. All participants provided a fasted blood sample and 
completed cognitive measures of verbal episodic learning and memory (considered 
as the most sensitive and specific marker of age-related cognitive decline). The 
principle findings of this study suggest an association between higher VD status and 
poorer performance on verbal episodic memory in middle-aged and older individuals 
with normal VD - iCa - PTH homeostasis and indicate the provision of VD 
 vi	  
supplements in individuals with adequate VD status may cause adverse cognitive 
outcomes.  
 
Taken together, the primary findings presented in Publication 1 and 
Publication 2 of this thesis support the broad hypothesis that the ‘Vitamin D –
Calcium - Parathyroid Hormone’ endocrinal axis has vascular modulating effects on 
cerebral capillary permeability. The experimental data from the animal studies 
provide novel insight into the detrimental effects of supplementary VD on cerebral 
capillary integrity and function, which may subsequently modulate neurocognitive 
function in a clinical context. The findings emphasize the importance of establishing 
an optimal concentration for serum VD that is ideal for cerebral capillary functioning 
and cognitive health.   
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Chapter 1 
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Chapter 1: Review of the Literature 
 
1.1 Introduction 
Population ageing is a growing global phenomenon in which the prevalence 
of chronic diseases has considerably increased (Cardoso, Cominetti, & Cozzolino, 
2013; Hasnain & Vieweg, 2014). Dementia is the progressive decline in cognitive 
function and represents one of the greatest causes of institutionalisation, morbidity 
and mortality among the elderly. Indeed, the occurrence of dementia is rising; 
according to the World Health Organization, there are currently over 44 million 
people worldwide affected by dementia (Alzheimer's Disease International, 2009). 
Without further advances to current preventative measures, this number is expected 
to exceed 115 million by the year 2050, accounting for over 20% of the world’s 
population (Alzheimer's Disease International, 2009; Prince et al., 2013). 
 
Presently, dementia is regarded as the greatest cause of disability and 
dependence in older Australians aged over 65 years and the second leading cause of 
death in Australia (The Australian Institute of Health and Welfare, 2015). In 2014, 
approximately 332, 000 Australians were living with dementia (The Australian 
Institute of Health and Welfare, 2014). Reflecting a growing socio-economic burden 
on the health/residential aged care system, approximately $5 billion was reportedly 
spent on dementia-related health care between 2009-10 (The Australian Institute of 
Health and Welfare, 2012, 2014). Presently, there is no cure for dementia. Despite 
significant research and development of several pharmacological strategies, effective 
disease-modifying therapies have been largely unsuccessful in terms of slowing 
disease progression. Clearly, identifying preventative strategies to reduce dementia 
risk and delaying disease onset and progression are global public health priorities to 
address the ‘most significant health crisis of the 21st Century’ (Alzheimer's Disease 
International, 2010). 
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1.1.1 Dementia 
Dementia is the term used to describe a clinical syndrome caused by 
neurodegeneration, more commonly affecting the older population. Dementia is 
clinically characterised by the progressive deterioration of an individual’s cognitive 
capacity and behavioural abnormalities that affect memory, intellect and ability to 
rationalise, physical functioning and capacity for independent living (Grand, Caspar, 
& Macdonald, 2011). Late-onset Alzheimer’s disease (AD) and vascular dementia 
(VaD) are widely recognised as the most common causes of age-related dementia, 
accounting for over two-thirds of diagnosed cases (Fotuhi, Hachinski, & 
Whitehouse, 2009; Kelley & Petersen, 2007). The pathological hallmarks of AD and 
VaD frequently coexist and only a small percentage of individuals diagnosed with 
dementia exhibit AD without vascular abnormalities (de la Torre, 2004; Duron & 
Hanon, 2008; Fotuhi et al., 2009; Iadecola, 2010).  
 
1.1.1.2 Pathophysiology of late-onset Alzheimer’s disease 
The underlying pathophysiology of late-onset AD-type remains complex and 
is still not entirely understood. Potential causative mechanisms for late-onset AD 
have been extensively considered throughout the literature and include neuro-
inflammation, oxidative neuronal damage, neurotoxicity, and genetic vulnerability 
(Grammas, 2011; Zlokovic, 2008). 
 
Late-onset AD is pathologically defined by hallmark features including brain 
tissue atrophy, cerebral extracellular deposition of amyloid-β peptide, intra-neuronal 
neurofibrillary tangles consisting of hyper-phosphorylated microtubule-associated 
protein tau, neuronal degeneration, disrupted cholinergic neurotransmission, and 
extensive cerebrovascular abnormalities including neurovascular damage and 
inflammation (Ellis et al., 1996; Fukuoka, Nakayama, & Doi, 2004; Heneka et al., 
2015; Mattson, 2004; Miyakawa, 2010; Mufson, Counts, Perez, & Ginsberg, 2008; 
Perl, 2010; Takata & Kitamura, 2012). Neuronal cell death has been associated with 
the development of senile plaques and tangles, particularly in the hippocampal and 
cortex regions of the brain, mainly associated with learning and memory (Mattson, 
2004). Whilst AD research over the past few decades has primarily focused on the 
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latter clinical stages of the disease related to aberrant deposition of protein 
constituents, mounting evidence has implicated a vascular origin for the disease as 
cerebrovascular changes may precede the clinical diagnosis of AD by years 
(Blennow et al., 1990; Dickstein et al., 2010; Grammas, 2000; Kalaria, 1992, 1999; 
Zlokovic, 2008).  
 
1.2 Barriers of the central nervous system 
In order to maintain central nervous system (CNS) homeostasis, it is crucial 
the composition of brain extracellular fluid is kept within precise physiological 
range, independent of fluctuations in the systemic circulation. There are three 
barriers of the CNS, namely, the arachnoid barrier, the blood-cerebrospinal fluid 
barrier (BCSFB) and the blood-brain barrier (BBB). These barriers work in 
conjunction to maintain a steady-state fluid ionic microenvironment for optimal 
cerebral function, to protect the CNS from any chemical insults by preventing the 
entry of pro-inflammatory mediators, macromolecules and neurotoxins into the 
brain, and to ensure the brain receives adequate nutrition from the peripheral 
circulation (Abbott & Friedman, 2012; Abbott, Patabendige, Dolman, Yusof, & 
Begley, 2010). 
 
1.2.1 Arachnoid epithelium and blood-cerebrospinal fluid barrier 
The arachnoid membrane essentially ‘envelops’ the brain beneath the dura 
mater layer and separates extracellular fluid of the CNS from the peripheral 
circulation (Abbott & Friedman, 2012). The avascular nature of the multi-layered 
epithelial layer and its small surface area relative to the blood-brain barrier does not 
represent a significant interface for blood-brain exchange (Cipolla, 2009). 
 
Cerebrospinal fluid (CSF) is separated from systemic circulation and cerebral 
blood flow by the BCSFB, located at the choroid plexuses of the brain. The BCSFB 
is comprised of tight junctions formed between the epithelial cells of the CSF-facing 
surface of the epithelium that exclude the diffusion of large or hydrophilic molecules 
into the CSF whilst allowing transport of hydrophobic molecules and metabolic 
products via specific protein transporters (Abbott et al., 2010).  
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1.2.2 Blood-brain barrier 
The BBB represents the major interface between the brain parenchyme and 
blood (Hawkins & Davis, 2005). The total length of cerebral capillaries in an adult 
human brain is approximately 600 km and the combined surface area of the BBB 
constitutes the largest surface area for blood-tissue exchange, averaging between 150 
and 200 cm2g-1, a total area of 15 m2 for exchange per average adult (Nag & Begley, 
2005). Unlike capillaries in other parts of the body, cerebral capillary vessels are 
comprised of tightly apposed endothelial cells that effectively ‘bind’ the adjacent 
cells and regulatory transport systems that restrict ion flux, paracellular diffusion and 
transcytosis, in order to regulate the neuronal microenvironment as demonstrated in 
Figure 1 (Abbott, Ronnback, & Hansson, 2006; Bradbury, 1993; Egleton & Davis, 
1997). The combination of specific carrier-mediated systems and short distance 
between adjacent capillary vessels (~ 40 μm) facilitates the rapid diffusion-mediated 
exchange of essential nutrients such as glucose, amino acids and vitamins into brain 
interstitial fluid, rapid diffusion of neurotransmitters and the active transport of 
metabolic waste products from neurons back to the systemic circulation (Abbott & 
Friedman, 2012; Abbott et al., 2010). 
 
The permeability of the BBB is modulated by the expression of tight junction 
and adherens junction proteins in order to protect the brain from systemically derived 
harmful neurotoxic and pro-inflammatory agents. Molecules greater than 400 kda in 
size are unable to permeate across the cerebral capillary layer (Hawkins & Davis, 
2005; Pardridge, 2012). The cerebral capillary endothelium is lined by the basement 
membrane separating astrocytes and pericytes of the outer lining of the BBB. Both 
astrocytes and pericytes are critically important in maintaining cell integrity, synaptic 
signal transmission, neuronal plasticity, and providing immune functionality to 
capillaries; often referred as the neurovascular unit (Abbott et al., 2006; Zlokovic, 
2005). 
 
A highly selective barrier system resulting from the combination of 
structural, chemical and functional characteristics of the arachnoid epithelium, the 
BCSFB and the BBB allow strict regulation between components of blood, brain and 
CSF. Physiological and pathological states can alter the strict microenvironment in 
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the CNS by modulating barrier permeability (Abbott et al., 2006; Weiss, Miller, 
Cazaubon, & Couraud, 2009; Zlokovic, 2008).  
 
 
 
Figure 1. Diagrammatic representation of the Blood-Brain Barrier.   
 
1.2.2.1 Cerebrovascular dysfunction & neurovascular 
inflammation in Alzheimer’s disease 
Structural damage or dysfunction of the cerebral capillary endothelium 
perturbs cerebral cellular homeostasis, transporter and enzymatic systems and 
subsequently limits the ability of the barrier to restrict blood-borne neurotoxic 
substances from entering the brain parenchyme (Herve, Ghinea, & Scherrmann, 
2008; Huber, Egleton, & Davis, 2001). A compromised BBB can range from mild, 
transient tight junction opening to chronic barrier dysfunction, where the latter has 
been implicated in the pathophysiology of a number of neurodegenerative and neuro-
inflammatory diseases (Forster, 2008; Persidsky, Ramirez, Haorah, & Kanmogne, 
2006; Petty & Lo, 2002). 
 
In primary neurodegenerative conditions such as AD, VaD, multiple sclerosis 
and epilepsy; and in secondary neurodegenerative disorders such as stroke, 
cerebrovascular integrity is impaired and consequently causes inappropriate blood-
to-brain parenchyme protein trafficking, a decrease in tight junction protein 
expression, neurovascular inflammation and if persistently exaggerated, neuronal 
apoptosis (Kalaria, 2010; Zlokovic, 2011). Pathological alterations associated with 
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altered cerebral capillary permeability include vascular endothelial and smooth 
muscle cell proliferation and has been consistently indicated in individuals with 
dementia of AD-type ((Ellis et al., 1996). Substantial endothelial cell necrosis 
reportedly coincided with BBB disruption in AD subjects (Claudio, 1996). 
Moreover, blood-specific plasma proteins have been reported in the brain 
parenchyme of AD subjects, observations consistent with impaired cerebral capillary 
endothelium (Kalaria, 1992; Wisniewski, Vorbrodt, & Wegiel, 1997; Zipser et al., 
2007). 
 
Based on the highly vascularised nature of the BBB, evolving research and 
supporting evidence suggests compromised cerebral capillary vessel integrity may be 
one of the primary causative factors of AD-dementia and may precede 
pathophysiological changes such as amyloidosis and tau-tangles (Bell & Zlokovic, 
2009; Brown & Thore, 2011; Gorelick et al., 2011; Zlokovic, 2008). These findings 
are further supported by recent novel findings from our laboratory of an age-
associated increase in cerebral capillary permeability and heightened neurovascular 
inflammation in otherwise healthy wild-type mice, preceded neuropathological 
sequeale (Takechi, Pallebage-Gamarallage, Lam, Giles, & Mamo, 2012). Studies by 
Chen et al. (2009) reported the extent of BBB breakdown coincides with the severity 
and duration of vascular disruption (Chen et al., 2009). Consistent with a causative 
role, recent experimental and clinical studies have shown therapeutic benefit in AD 
progression if cerebrovascular disturbances are corrected or attenuated (Gorelick et 
al., 2011; Takechi, Pallebage-Gamarallage, Lam, Giles, & Mamo, 2014). 
Nonetheless, modulation of cerebral capillary function with age-related diseases 
remains a poorly understood phenomenon.  
 
A chronic, heightened state of inflammation involving the up-regulation of 
complement molecules, pro-inflammatory cytokines, acute phase reactants and other 
inflammatory mediators have been extensively reported in the AD literature (Meraz-
Rios, Toral-Rios, Franco-Bocanegra, Villeda-Hernandez, & Campos-Pena, 2013; 
Zlokovic, 2011). Post-mortem AD tissue and experimental findings derived from 
small vessel disease murine models are consistent with impaired BBB integrity 
coinciding with the entry of neurotoxic blood-derived products into the brain 
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parenchyme (Erickson & Banks, 2013; Sengillo et al., 2013). The entry of neurotoxic 
molecules into the brain parenchyme causes the paracrine activation of surrounding 
astrocytes and pericytes, ultimately causing neuronal damage/death (Bell et al., 2010; 
Zipser et al., 2007). In cell culture studies, the exposure of inflammatory factors to 
bovine brain capillary endothelial cells, as an in vitro BBB model, directly increased 
the permeability of the cell layer and thereby modulated barrier function (Deli et al., 
1995; Grammas, 2011; Mark & Miller, 1999). Additionally, enhanced tight junction 
protein breakdown caused by extensive leucocyte recruitment upon exposure to 
inflammatory molecules was reported in an in vivo rat model (Bolton, Anthony, & 
Perry, 1998). Cerebral capillary dysfunction induced as a consequence of a 
chronically heightened state of systemic inflammation is positively associated with 
AD (Drake et al., 2011; Stolp et al., 2011; Takechi et al., 2010a). Moreover, the 
expression of inflammatory markers in the early stages of AD is associated with 
greater disease progression (Grammas, 2011). A number of population and 
experimental studies have reported the efficacy of anti-inflammatory/anti-oxidative 
pharmacological agents and certain environmental and nutritional factors in 
positively regulating BBB integrity via modulation of systemic inflammatory 
pathways (Ifergan et al., 2006; Kalayci et al., 2005; Pallebage-Gamarallage et al., 
2012; Pallebage-Gamarallage et al., 2010; Takechi, Galloway, Pallebage-
Gamarallage, Lam, & Mamo, 2010b; Takechi, Pallebage-Gamarallage, Lam, Giles, 
& Mamo, 2013b; Takechi et al., 2014).  
 
1.2.2.2 Blood-brain barrier and cognition 
Cognitive functioning is entirely dependent on the ability of neurons to form, 
maintain and break synaptic connectivity to other neurons (Lee & Silva, 2009). 
These processes are crucial for motor learning in the cerebellum and memory 
formation in the hippocampus and frontal cortex. Vascular risk factors have been 
associated with increased risk of cognitive impairment in both cross-sectional and 
longitudinal studies (Iadecola, 2013; Lorius et al., 2015). Many researchers have 
suggested that a ‘breached’ BBB increases the risk of neuronal damage and cognitive 
decline, however until recently, the initial area of damage was unknown. Montagne 
and colleagues (2015) reported cerebral capillary endothelium is firstly compromised 
in the hippocampal formation, the hippocampal sub-region CA1 and the dentate 
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gyrus, in older aged adults and thought to contribute to the early stages of age-related 
cognitive impairment (Montagne et al., 2015). Moreover, pericyte injury was shown 
to correlate with the extent of BBB damage (Montagne et al., 2015). Previous studies 
by Wang and colleagues (2006) also reported increased hippocampal endothelial 
permeability in subjects with mild cognitive impairment (defined as the clinical stage 
prior to progression to AD) when compared to age-matched controls (Wang, Golob, 
& Su, 2006). On this basis, it is important to address vascular risk factors involved in 
BBB dysfunction in aim to reduce the prevalence of cognitive impairment and AD 
progression.  
 
1.3 Vitamin D 
1.3.1 Importance of nutrition in brain function 
Over the past few decades, there has been extensive research in the field of 
nutrition and the ageing population (Cardoso et al., 2013; Scott et al., 2006; 
Swaminathan & Jicha, 2014; Tucker et al., 1990). Whilst ageing is considered a 
primary risk factor of AD, there is strong epidemiological evidence and intervention 
trial data linking nutritional deficiencies with the exacerbation of neurodegenerative 
disease progression and cognitive deterioration (Cherubini et al., 2005; da Silva et 
al., 2014; Solfrizzi et al., 2011; Tucker, Qiao, Scott, Rosenberg, & Spiro, 2005). 
Elderly individuals with insufficient dietary intake of certain micronutrients and 
vitamins generally perform poorer in cognitive assessments when compared to 
controls (Requejo et al., 2003; Rosenberg & Miller, 1992; Tucker et al., 2005). AD-
individuals commonly present with inadequate levels of specific micronutrients and 
vitamins and may be associated with increased risk of adverse brain function and 
thereby disease progression. However, cognitive dysfunction is commonly associated 
with progressive changes in eating behaviour and dietary deficiencies may therefore 
be consequential. Currently, widespread use of vitamin and mineral supplements has 
been promoted among the community to promote brain/cognitive function (Buell et 
al., 2010). Vitamin D (VD) has generated substantial interest in the dementia field 
based principally on its non-classical roles in the brain and neurocognitive health.  
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1.3.2 Sources and metabolism of vitamin D  
Vitamin D is a lipid soluble vitamin first discovered by McCollum and 
colleagues in 1922 (McCollum, Simmonds, Becker, & Shipley, 1922). This steroid 
hormone is involved in the regulation of various essential physiological functions 
related to the maintenance of mineral ion homeostasis and skeletogenesis (Bikle, 
2014). In recent years, VD has been implicated with a number of functions unrelated 
to its classical role in systemic calcium homeostasis including neuroprotection and 
modulating inflammation (Holick, 2003). 
 
1.3.2.1 Sources of vitamin D 
Vitamin D is obtained from two distinct sources; either from dietary sources 
or via skin photosynthesis. The main forms of VD present in foods are 
cholecalciferol (vitamin D3), derived from animal sources, and ergocalciferol 
(vitamin D2), of plant-based origin. Vitamin D3 can also be synthesized endogenously 
through exposure to sunlight. The latter is considered the main source of VD for the 
human body as the human diet is not rich in either forms of VD, hence the 
widespread promotion of food fortification and supplement usage in some urbanised 
settings. Upon exposure of the subcutaneous VD prehormone 7-dehydrocholesterol 
to ultraviolet B radiation (wavelength 290 – 320 nm), endogenous vitamin D3 is 
rapidly formed (DeLuca, 2004). Feedback mechanisms ensure the degradation of VD 
to inactive photoproducts upon excessive exposure to sunlight minimises the risk of 
VD intoxication (Holick, 2007). 
 
1.3.2.2 Metabolism of vitamin D 
Vitamin D3 is considered a pro-hormone rather than a true vitamin and 
requires two sequential hydroxylations for conversion to its active metabolite, 
calcitriol (1α, 25-dihydroxyvitamin D3). VD is transported through the circulation 
bound to its carrier protein known as the VD binding protein and undergoes the first 
hydroxylation in the liver or locally in other organs, converting VD to calcidiol (25-
hydroxyvitamin D (25(OH)D); considered the stable marker of VD status) by 25-
hydroxylase followed by renal hydroxylation by the 1 α-hydroxylase enzyme, 
CYP27B1, which generates calcitriol responsible for regulating gene expression; see 
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Figure 2 (Boucher, 2012; DeLuca, 2004; Lips, 2006; Norman, 2008) A number of 
VD metabolites are generated as a result of activation the VD precursors and whilst it 
has been proposed all hydroxylated forms of VD can bind to the VD receptor (VDR), 
serum concentrations of these metabolites are generally too low to exert a significant 
biological response (Tuohimaa, Keisala, Minasyan, Cachat, & Kalueff, 2009).  
 
The conversion of VD to calcidiol is uncontrolled and the rate of conversion 
is dependent on the exogenous supply of VD.  Whilst this metabolite is considered as 
the storage form of the pre-hormone prior activation, renal calcitriol synthesis is 
strictly controlled by endocrinal feedback mechanisms. The synthesis of VD and its 
metabolism is closely coupled to calcium homeostasis and is modulated by 
parathyroid hormone (PTH), calcium and phosphorus concentrations. Calcium and 
PTH positively regulate CYP27B1 activity, whilst negative regulators of this enzyme 
include phosphate, fibroblast-growth-factor 23, klotho and calcitriol itself, inducing 
VD catabolism (Dusso, Brown, & Slatopolsky, 2005; Holick & Chen, 2008; 
Kovesdy & Quarles, 2013). Calcitriol acts as a nuclear hormone and is the only high 
affinity ligand for the VDR (Haussler et al., 1998; Pike & Meyer, 2010). The effects 
of vitamin D are mediated via the binding of calcitriol to the VDR. For example, a 
decrease in circulating calcium elicits PTH release by the parathyroid glands thereby 
stimulating renal CYP27B1 activity to induce synthesis of calcitriol. To reinstate 
calcium levels, calcitriol reduces renal calcium excretion, increases intestinal 
calcium absorption and stimulates osteoclastic activity for calcium release in bones. 
Interestingly, VDR is expressed in a number of human tissues and cell types, 
including those irrelevant to bone formation and calcium homeostasis.  
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Figure 2. Activation pathway of vitamin D metabolism  
 
1.3.3 Vitamin D in the central nervous system 
The human brain is capable of locally synthesizing calcitriol and indeed, the 
expression of the VDR is widely expressed in both neuronal and glial cells within 
particular brain structures particularly vulnerable to age-related degeneration, 
namely, the cortex, hippocampus and the cerebellum (Eyles, Smith, Kinobe, 
Hewison, & McGrath, 2005; Wang, Zhu, & DeLuca, 2012; Zehnder et al., 2001). 
Furthermore, the VDR and its enzyme are colocated in the brain. The widespread 
distribution of the VDR in both humans and rodents are similar and indeed, strong 
!
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VDR expression in the neuroepithelium of neonatal rats during early neurogenesis 
has also been reported (Eyles et al., 2005; Veenstra et al., 1998). In addition to the 
discovery of VDR and its enzyme in brain tissue, VD has been shown to cross the 
BBB and thus suggesting a physiological functional effect of VD on the CNS 
(Holmoy et al., 2009). According to Holmoy and colleagues (2009), the 
concentration of VD in the CSF positively correlates with that in serum under 
physiological conditions (Holmoy et al., 2009). Indeed, epidemiological and 
experimental studies have postulated VD generally has a protective role in 
neurocognitive function and cerebrovascular disease although the mechanisms for 
these purported benefits remain unclear (Annweiler et al., 2009; Farid et al., 2012; 
Tuohimaa et al., 2009).  
 
1.3.3.1 Neuroprotective properties of vitamin D 
Recent prospective studies have shown a beneficial association of VD and 
numerous age-related disorders and suggest that VD may be neuroprotective via 
vascular mechanisms (Buell & Tucker, 2011). Data from animal studies have 
implied that VD may modulate the expression of neurotrophins and calcium binding 
proteins to avoid excitotoxicity for normal brain function (Brewer et al., 2001; Eyles, 
Brown, Mackay-Sim, McGrath, & Feron, 2003; Ibi et al., 2001). There is also 
evidence that VD exhibits anti-oxidant and immuno-regulatory properties to suppress 
oxidative damage and the expression of pro-inflammatory cytokines (Garcion et al., 
1998; Mathieu et al., 2004; Wobke, Sorg, & Steinhilber, 2014). Briones et al. (2012) 
and others reported that VD may modulate an exaggerated pro-inflammatory state 
associated with ageing, which also coincided with attenuation of amyloid 
accumulation (Briones & Darwish, 2012; Durk et al., 2014; Yu et al., 2011). Moore 
et al. (2005) successfully demonstrated that VD acts as an anti-inflammatory agent 
by attenuating the age-related up-regulation of inflammatory cytokines and down-
regulation of anti-inflammatory cytokines (Moore, Piazza, Nolan, & Lynch, 2007; 
Moore, Piazza, McCartney, & Lynch, 2005). In addition, VD was found prevent 
ischemic-induced BBB dysfunction in cultured cerebral endothelial cells by 
protecting them from reactive oxygen species (ROS) and pro-inflammatory 
cytokines (Won et al., 2015). Experimental findings demonstrated significant up-
regulation of CYP27B1 and VDR expression upon exposure of cultured brain 
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pericytes to inflammatory mediators suggesting VD-related autocrine/paracrine 
feedback mechanisms in the BBB (El-Atifi, Dreyfusm, Berger, & Wion, 2015; 
Nissou et al., 2014). Conversely, recent findings by Barker and colleagues (2015) 
showed the treatment of VDD with VD supplementation increase the pro-
inflammatory phenotype (Barker et al., 2015). Additional neuroprotective attributes 
of VD may include regulation of neurophysiological mechanisms via enhanced 
neurotransmission, synthesis of neurotrophic factors, up-regulated dendritic growth 
and neuronal preservation (Buell & Dawson-Hughes, 2008; McCann & Ames, 
2008).  
1.3.4 Global prevalence of vitamin D deficiency 
It has been estimated over 1 billion individuals worldwide are either vitamin 
D deficient (VDD) or insufficient and this phenomenon is particularly prevalent in 
the ageing population (Boucher, 2012; Holick et al., 2012; Holick & Chen, 2008; van 
Schoor & Lips, 2011). Circulating concentrations less than 50 nmol/L and 75 nmol/L 
of VD generically define clinical VDD and VD insufficiency, respectively. Lips and 
colleagues (2006) report that major causes of VDD include inadequate sun exposure, 
dietary deficiencies, impaired absorption, increased secretion, obesity, and advanced 
age (Lips, 2006).  
 
The interest in the potential importance of VD in human health continues to 
expand, particularly in the prevention of neurodegenerative diseases. Increasing 
evidence has implicated VDD as a substantial risk factor of inflammatory-related 
disorders/diseases including, cancer, diabetes, obesity, hypertension, cardiovascular 
disease, and all-cause mortality (Clemente-Postigo et al., 2015; Schottker et al., 
2013; Weng et al., 2013; Yin & Agrawal, 2014). Moreover, numerous cross-
sectional and longitudinal studies have shown an inverse correlation between VD 
status and disorders of the CNS such as multiple sclerosis, stroke, schizophrenia, 
Parkinson’s disease, and AD (Annweiler, Llewellyn, & Beauchet, 2013a; Ascherio et 
al., 2014; Balion et al., 2012; DeLuca, Kimball, Kolasinski, Ramagopalan, & Ebers, 
2013; Dickens, Lang, Langa, Kos, & Llewellyn, 2011; Eyles, Burne, & McGrath, 
2013; Itzhaky et al., 2012; Suzuki et al., 2013). The widespread insufficiency of VD 
suggests a range of physiological functions related to this vitamin. Collectively, these 
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findings are suggestive that greater VD status may have beneficial effects for brain 
heath, however larger clinical and randomised controlled trials are required to 
elucidate whether these effects are causally associated to disease pathogenesis or a 
marker of health.  
 
1.3.4.1 Cell culture and animal models of vitamin D deficiency  
A number of experimental studies have demonstrated the neuroprotective 
features of VD. Findings by Wang et al. (2001) reported the pre-treatment of VD 
attenuated the effects of various stressors, including 6-hydroxydopamine-induced 
neurotoxicity (Wang et al., 2001). In addition, adult VDD was strongly associated 
with substantial changes in behaviour and brain neurochemistry in the mouse 
(Groves et al., 2013). Studies by Latimer et al. (2014) postulated a causal 
relationship between VD status and cognitive function via VD-mediated of 
hippocampal gene expression in aged rats models with altered VD homeostasis 
(Latimer et al., 2014). VDD in adult rats have been shown to exacerbate stroke-
related cerebrovascular injuries, accompanied by severe post-stroke behavioural 
abnormalities (Balden, Selvamani, & Sohrabj, 2012). Keeney and colleagues (2013) 
reported chronic VDD causes elevated tyrosine nitration stress, alterations in glucose 
metabolism and mitochondrial changes in the brain of middle to older aged rats 
(Keeney et al., 2013a). Calcitriol reportedly reduced cerebral amyloid accumulation 
and improved cognitive functioning in mouse models of AD (Durk et al., 2014). 
VDR and 1α-hydroxylase knockout mice also exhibit a premature ageing phenotype 
coinciding with VDD accompanied by severe hypocalcemia, hypophosphatemia and 
secondary hyperparathyroidism (Keisala et al., 2009; Lanske & Razzaque, 2007). 
Conversely, a recent study based on 16 to 20 week-old VDD rats subjected to 
chronic consumption of VDD diets showed no major impairment in behaviour, 
although subtle effects were observed in tasks related to attention processing and 
neurotransmitter signalling in the striatum (Byrne et al., 2013). Moreover, Brouwer-
Browlsma et al. (2014) found no differential effects between 22-month old mice fed 
either control or a VDD diet for 12 months (Brouwer-Brolsma et al., 2014). An 
interesting study by Solomon et al. (2011) demonstrated VD dietary restriction 
improved early disease severity and delayed disease onset in a mouse model of 
amyotrophic lateral sclerosis when compared to a diet with adequate VD, however 
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performance functional outcomes were reduced upon disease onset (Solomon, 
Gianforcaro, & Hamadeh, 2011). 
 
Collectively, experimental studies investigating the mechanisms of VD 
neuroprotection remain inconclusive. It is clear however, no studies to date have 
explored if there is a direct effect of VD on the permeability of the cerebral capillary 
endothelium, which is purportedly associated with cognitive performance and 
progression of some neurodegenerative disorders. There is emerging evidence that 
higher concentrations of VD may also be associated with an increased risk of chronic 
diseases.  
 
1.3.4.2 Hypervitaminosis D 
Based on the tight regulation of VD activation, hypervitaminosis is rare in 
humans based on dietary sources. The prevalence of VD supplementation during the 
early periods of synthetic fortification, early ageing, hypercalemia, cardiovascular 
complications (vascular-related) and early death was reported in children, supporting 
the association between hypervitaminosis D and accelerated ageing (Markestad et al., 
1987; Oliveri, Cassinelli, Mautalen, & Ayala, 1996). Furthermore, mutant mice with 
accelerated ageing phenotypes occur concomitant with hypervitaminosis D 
(Tuohimaa et al., 2009). 
 
Fibroblast growth factor 23 (FGF-23) and Klotho are secretory proteins 
involved in the regulation of mineral homeostasis and have recently emerged as key 
mediators in early ageing (Medici et al., 2008; Razzaque & Lanske, 2006; 
Tsujikawa, Kurotaki, Fujimori, Fukuda, & Nabeshima, 2003). Genetic ablation of 
FGF-23 or Klotho genes in rodent models result in hypervitaminosis D, 
hypercalcemia and hyperphosphatemia; corresponding with a phenotype consistent 
with premature ageing (Medici et al., 2008; Razzaque & Lanske, 2006; Torres et al., 
2007). Tsujikawa et al. (2003) and others reported dietary restriction of VD reverses 
the premature-ageing phenotypes and prolongs survival (Madathil, Coe, Casu, & 
Sitara, 2014; Tsujikawa et al., 2003). These findings provide strong evidence that 
hypervitaminosis D may be causally associated with the ageing process. 
Furthermore, Huebbe et al. (2011) presented experimental evidence that the APOE 
 17	   
ε4 allele, a positive risk factor of AD, is associated with higher serum VD levels 
(Huebbe et al., 2011). Increased levels of VD can trigger apoptosis and result in 
tissue atrophy upon periods of prolonged exposure (Johnson, Muindi, Hershberger, 
& Trump, 2006; Medici et al., 2008; Narvaez & Welsh). Excessive activation of the 
VDR causes gene transcription associated with mitochondrial export of cytochrome 
C and subsequent cleavage of caspase-9, which consequently promotes DNA 
fragmentation and thereby apoptosis (Demay, 2006).  On the basis of these findings, 
it appears an optimal concentration of VD must be determined for optimal brain 
function due to the complications involved with hypo-and-hypervitaminosis.  
 
1.3.4.3 Vitamin D and cognition 
Higher vitamin D status, represented by greater serum concentrations of 
25(OH)D has been associated with better cognitive performance in some, though not 
all studies (Bartali, Devore, Grodstein, & Kang, 2014; Buell et al., 2010; Granic et 
al., 2015b; Littlejohns et al., 2014; Oudshoorn, Mattace-Raso, van der Velde, Colin, 
& van der Cammen, 2008). An international task force considering VD and cognition 
in the older population recently concluded that hypovitaminosis increases the risk of 
cognitive decline and dementia in older adults (Annweiler et al., 2015). Indeed, 
hypovitaminosis D is associated with purportedly 2.4 times higher risk of cognitive 
impairment, specifically with AD, compared to individuals with normal levels of the 
vitamin (Annweiler et al., 2009; Annweiler et al., 2013a; Annweiler et al., 2013b; 
Etgen, Sander, Bickel, Sander, & Forstl, 2012; Littlejohns et al., 2014).  
 
Hooshmand and colleagues (2014) reported positive associations between 
VD status with cognitive function, CSF amyloid-β and brain tissue volumes 
(Hooshmand et al., 2014). Regional cerebral blood flow and brain function was 
found positively correlated with VD concentrations in AD patients (Farid et al., 
2012). A lower concentration of serum VD correlates well with certain deficits in 
executive functioning (a heterogeneous set of higher level processes that control and 
regulate other abilities and behaviour), however, episodic memory was found to be 
unaffected (Annweiler et al., 2013b; Brouwer-Brolsma et al., 2013; Granic et al., 
2015b). Conversely, results also indicated cognitive impairment was more prevalent 
in individuals with higher levels of VD, especially those taking VD supplements 
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(Granic et al., 2015b; McGrath et al., 2007). A number of prospective cohort studies 
have failed to show a correlation between VD and cognitive performance, ranging 
from early childhood to advanced aged individuals (Dean et al., 2011; Maddock, 
Geoffroy, Power, & Hypponen, 2014; Schneider et al., 2014; Tolppanen, Williams, 
& Lawlor, 2011).  
 
Given that sun exposure and subsequent skin synthesis is a major source of 
VD, studies (especially cross-sectional and short-follow ups) exploring the 
association of VD homeostasis with cognition in late-aged individuals may be 
confounded by ‘reverse causation’ due to lifestyle changes and immobility. 
Moreover, the ability to synthesize endogenous VD declines with age and may be 
due to morphological changes due to biological ageing (Holick, Matsuoka, & 
Wortsman, 1989; MacLaughlin & Holick, 1985). As a lipid soluble vitamin, VD is 
typically stored in adipose tissue. As ageing is generally associated with increased 
overall body fat composition, it is possible that individuals diagnosed as VDD are in 
fact VD adequate and incorrectly diagnosed (Konradsen, Ag , Lindberg, Hexeberg, 
& Jorde, 2008).  
 
As the majority of the available literature is primarily focused on VDD 
populations, evidence suggests individuals with low VD levels are likely to benefit 
from supplementation. A biphasic U-shaped relationship has been used to describe 
the association between VD status and the risk incidence of chronic diseases such as 
cardiovascular disease, prostate cancer, and all-cause mortality (Durup et al., 2015; 
Tuohimaa et al., 2004). A biphasic relationship has also been suggested between VD 
status and global cognition in the elderly, whereby moderate VD concentrations are 
deemed beneficial but in cases of deficits or excess the putative neuroprotective 
properties of VD are lost (Granic et al., 2015b). Figure 3 represents the purported U-
shaped association between serum VD concentration and the risk of chronic diseases 
and cognitive dysfunction. Indeed, results from the Women’s Health Initiative found 
that VD and calcium supplementation for over a period of 8 years had no effects on 
cognition (Rossom et al., 2012). Moreover, studies by Stein et al. (2011) show that 
supraphysiological doses of VD may not be essential to exert a beneficial cognitive 
effect (Stein, Scherer, Ladd, & Harrison, 2011). Further increasing VD beyond 
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sufficient levels evidently leads to adverse cognitive outcomes. The health risks and 
benefits from VD and calcium supplementation remain controversial where 
numerous clinical studies have implicated increased risk of vascular events and white 
matter lesions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Purported biphasic U-shaped relationship between Vitamin D status and 
the risk of chronic diseases and cognitive decline 
 
1.4 Calcium 
An equivocal function of VD is to regulate calcium metabolism. Calcium is 
the fifth most abundant element in the body and arguably the most widespread and 
ubiquitous signalling molecules in mammalian cells and has been implicated in a 
number of neurodegenerative diseases in the past few decades, particularly dementia 
(Berridge, Bootman, & Lipp, 1998; Berridge, Lipp, & Bootman, 2000; Peacock, 
2010). 
 
1.4.1 Calcium physiology 
A complex, integrated system involving the actions of VD, PTH and 
calcitonin, is required for the strict regulation of calcium homeostasis. PTH and VD 
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are the main regulators of calcium homeostasis and have major regulatory effects on 
each other (Chattopadhyay, 2000; Silver, Yalcindag, Sela-Brown, Kilav, & Naveh-
Many, 1999). 
  
The majority of calcium of the body is stored as skeletal hydroxyapatite and a 
small portion is rapidly exchangeable calcium is found between extracellular fluid in 
bone found between osteoblasts, osteocytes and bone matrix. Only a small 
percentage of calcium comprises the extracellular and intracellular calcium 
concentration of the body, indicative of its potency and importance in cellular and 
vascular functions. 
 
1.4.1.1 Extracellular calcium 
Extracellular calcium is ultimately the source of all intracellular calcium ions 
and is crucial in blood coagulation, maintenance of skeletal integrity, intercellular 
adhesion and plasma membrane integrity (Brown, 1999). Extracellular serum 
calcium exists in three main fractions; approximately one half of total serum calcium 
is bound primarily to plasma proteins such as albumin, a small percentage is 
complexed to anions such as phosphate, bicarbonate, sulphate, and lactate, and the 
remaining one half circulates as the free divalent cation, ionised calcium. Ionised 
calcium (iCa) is the physiologically active fraction whereas the protein-bound and 
complexed forms of calcium are considered biologically inert and used as storage or 
buffering systems (Shane & Irani, 2006). 
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Figure 4. Extracellular calcium homeostasis feedback regulation 
 
 
Under normal homeostatic mechanisms, total serum calcium is kept between 
2.1 to 2.5 mM whilst iCa is strictly controlled by its hormonal counterparts between 
1.1 to 1.3 mM. The calcium-sensing receptor (CSR) is abundantly distributed in all 
tissues related to calcium control and small changes in circulating calcium levels 
trigger intracellular signalling pathways to exert feedback mechanisms (see Figure 
4). In response to low serum levels of iCa, chief cells of the parathyroid gland 
promote the synthesis and secretion of PTH, which rapidly stimulates the activation 
of VD. VD and PTH thereafter synergistically increase serum iCa via enhancing 
intestinal absorption of dietary calcium, increasing osteoclast activity to liberate 
calcium and reducing renal calcium excretion. Once calcium levels have been 
restored, negative endocrinal feedback mechanisms take place and suppress PTH 
synthesis and secretion. 
 
1.4.1.2 Intracellular calcium signalling 
Intracellular calcium acts as an important secondary messenger and involved 
in a number of crucial cellular functions including, gene transcription, cell 
proliferation, cell migration, neurotransmission and of particular interest, the 
modulation of the permeability of the brain capillary endothelium (Abbott, 1998; 
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Berridge, Bootman, & Roderick, 2003). The concentration of calcium and the 
signalling over cellular compartments is strictly controlled via diffusional and active 
transport systems that allow rapid removal of intracellular calcium from cytosolic 
space. The flux of calcium across plasma membrane and between intracellular 
compartments generates synaptic signalling and plays a vital role in neuronal 
functioning. Cytosolic calcium levels are maintained at extremely low concentrations 
of ~100 nm, approximately 10,000 to 20 000-fold less than the extracellular milieu 
during resting state (Zündorf & Reiser, 2011). This gradient is maintained by 
calcium-binding buffering proteins and via intrinsic membrane transport systems 
responsible for transport into organelles for intracellular storage or removal of 
calcium from cytosol back into extracellular space (Abbott, 1998). 
 
It is crucial local and global levels of calcium are strictly controlled at 
temporal and spatial levels as increases in calcium can lead to the activation of 
numerous cellular signalling pathways including those for learning and memory, as 
well as apoptotic pathways (Green, 2009).  
 
1.4.2 Central theory of calcium and ageing 
The potential critical role of cellular calcium in neuronal ageing was first 
postulated almost three decades ago and commonly referred to as the ‘Calcium 
Hypothesis of neuronal ageing’ (Khachaturian, 1987; Landfield, 1987). Based on the 
role of calcium as an upstream messenger in multiple signalling cascades, 
dysregulation of calcium homeostasis modulates cellular physiology, molecular 
functions and ultimately cell structure (Toescu, Verkhratsky, & Landfield, 2004). 
Whilst brief elevations of intracellular calcium are required for controlling 
membrane excitability and modulating essential processes such as learning, memory 
and gene transcription, chronic elevations in intracellular calcium triggers neurotoxic 
signalling cascades that lead to neuronal death (Arundine & Tymianski, 2003; 
Delorenzo, Sun, & Deshpande, 2005). The ‘Calcium Hypothesis’ states that impaired 
calcium signalling and synaptic plasticity caused by sustained elevations of calcium 
transients associated with ageing consequently compromises neuronal 
communication resulting in impaired cognition, memory formation and 
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neurodegeneration (Mattson, 2007; Mattson & Chan, 2003). Indeed, experimental 
and clinical studies have demonstrated brain neuronal calcium dyshomeostasis in 
both models of ageing and AD (Bruno et al., 2012; Hopp et al., 2015; Murchison et 
al., 2009; Thibault, Gant, & Landfield, 2007). Electrophysiological studies of 
hippocampal neurons have consistently shown significant altered calcium influx and 
transients (Disterhoft, Moyer, Thompson, & Kowalska, 1993; Raza et al., 2007; 
Thibault, Hadley, & Landfield, 2001).  
 
1.4.3 Calcium and the blood-brain barrier 
Strict regulation between extracellular and intracellular calcium 
concentrations is crucial in maintaining the paracellular permeability of the BBB by 
moderating junctional and cytoskeletal protein components (De Bock et al., 2013; 
Somjen, 2004). Normal BBB function is perturbed when extracellular calcium 
concentration is either decreased and/or intracellular free calcium concentration is 
increased, though the exact mechanisms involved require clarification (De Bock et 
al., 2013). Both hyper - and - hypocalcemic conditions have been shown to disrupt 
cell-cell contact of the junction protein formation and thereby increasing 
permeability and reducing trans-epithelial resistance of the cell layer; restoration of 
calcium levels restored normal barrier function (Brown & Davis, 2002). 
 
The importance of maintaining calcium homeostasis is further reinforced by 
the pioneering studies by Murphy and colleagues who demonstrated the role of the 
BBB and BCSFB in regulating the CNS during chronic hypo-or-hypercalcemic 
conditions (Murphy & Rapoport, 1988; Murphy, Smith, & Rapoport, 1986; Murphy, 
Smith, & Rapoport, 1988; Murphy, Smith, & Rapoport, 1989) It is still unclear 
whether serum calcium is directly related to the extracellular levels of calcium in the 
brain. It was reported that calcium levels in the brain and CSF do not change in 
proportion to acute or chronic changes of plasma iCa (despite chronic changes of up 
to 50% in plasma calcium), thus suggesting that calcium transport is primarily 
regulated by saturable transport mechanisms at the BBB (Murphy, Smith, & 
Rapoport, 1991). On the contrary, Tai et al. (1986) reported that calcium ions could 
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enter the brain via passive diffusion through the BBB, where serum calcium directly 
correlated with brain and CSF concentrations (Tai, Smith, & Rapoport, 1986). 
 
1.4.4 Calcium and cognitive function 
Consistent with the ‘Calcium Hypothesis’ several studies have implicated an 
association between serum iCa and global cognition. Schram et al. (2007) and others 
reported greater baseline serum calcium concentration associated with impaired 
cognitive performance in older aged adults (Schram et al., 2007; Tilvis et al., 2004). 
Moreover, the APOE ε4 allele (related to a 3-fold increase of developing AD) has 
also been associated with higher serum calcium and cognitive decline (van Vliet, 
Oleksik, Mooijaart, de Craen, & Westendorp, 2009). Neurotoxic effects of APOE ε4 
were linked with disrupted neuronal calcium homeostasis by increasing the 
intracellular calcium levels by influx of extracellular calcium. Experimental studies 
have shown amyloid-β aggregation may be involved in the disruption of intra-
neuronal calcium levels, by forming calcium permeable channels into neuronal 
membranes (Green, 2009). As per biphasic responses of nutrients and vitamins, high 
concentrations of calcium are considered harmful. Excess calcium causes aberrant 
aggregation of proteins and nucleic acids, modulates the integrity of lipid membranes 
and promotes phosphate precipitation (Verkhratsky, Rodriguez, & Parpura, 2012). 
 
A recent meta-analysis observed calcium supplementation (both with and 
without co-administration of VD) is associated with an increased risk of vascular-
related events (Bolland et al., 2010; Bolland, Grey, Avenell, Gamble, & Reid, 2011). 
Payne and colleagues (2008, 2013, 2014) have published several cross-sectional 
studies relating exaggerated iCa serum concentrations with cerebral white matter 
lesions (often associated with cognitive decline), larger brain lesion volumes and the 
induction of the apoptotic cascade (de Groot et al., 2000; Payne, Anderson, & 
Steffens, 2008; Payne, McQuoid, Steffens, & Anderson, 2014; Payne, Pierce, 
McQuoid, Steffens, & Anderson, 2013). Elevated serum calcium levels have been 
linked with higher risk of myocardial infarctions, other cardiovascular events, stroke 
and mortality (Jorde, Sundsfjord, Fitzgerald, & Bonaa, 1999; Leifsson & Ahren, 
1996; Wang et al., 2014). Consistent with the literature, a pro-inflammatory and pro-
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oxidant phenotype was found to be associated with hypercalcemia (Orrennius, 
Burkitt, Kass, Dypbukt, & Nicotera, 1992; Rezic-Muzinic et al., 2013). However, 
data reported by Talmor-Barkan et al. (2009) demonstrated hypocalcemia was 
associated with an inflammatory state (Talmor-Barkan et al., 2009a). 
 
If iCa is central to the neurovascular effects of VD, then by extension of 
clinical observations, VD supplementation would notionally be beneficial for 
subjects with hypocalcemia, but possibly harmful in subjects with elevated or 
adequate levels of serum calcium. Similar to VD, the effects of iCa on capillary 
permeability and inflammation have not been directly investigated and based on the 
interplay of both metabolites, their interactive effects need to be considered in 
conjunction with one another.  
 
1.4.5 Calcium paradox 
The calcium paradox is a well-known pathophysiological phenomenon based 
on the observations made on a calcium-depleted isolated rat heart preparation where 
severe myocardial injury and necrosis occurred in response after calcium repletion 
(Zimmerman et al., 1967). Thus if considered in context of AD, the calcium paradox 
is the parathyroid hormone-induced neuronal intracellular calcium overload triggered 
by calcium deficiency, which ultimately relates back to the ‘Calcium Hypothesis’. 
 
1.5 Parathyroid hormone 
As an important regulator of calcium homeostasis and potential role in the 
calcium paradox, PTH has been positively implicated with cognitive decline and 
dementia (Braverman et al., 2009; Dotzenrath et al., 2006). The role of PTH function 
has not been investigated independently in context of neurodegeneration as the 
manifestations of hyperparathyroidism are commonly thought to be secondary to 
hypercalcemia or VDD.  
1.5.1 Parathyroid hormone physiology 
The main physiological role of PTH is to function as a ‘calciostat’ to 
maintain extracellular levels of circulating calcium (Tabatabai & Jan De Beur, 2005). 
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The hormone is synthesized as a pre-propeptide subsequently cleaved to a 
biologically active 84 amino acid peptide. Full biological activity resides in the first 
34 amino-terminal amino acids of the PTH molecule. PTH is secreted by chief cells 
of the parathyroid glands and is tightly regulated on a transcriptional and post-
transcriptional level, dependent on calcium concentrations. Moreover, PTH regulates 
phosphorus levels and reciprocally, increased levels of phosphorus stimulate the 
synthesis and secretion of PTH due to reduced circulating calcium. PTH does not 
have a binding hormone and binds to PTH receptors on osteoblasts and epithelial 
cells of the nephron, where the conversion of VD is metabolised to calcitriol. To 
ensure steady-sate, PTH and VD mediate the mobilisation of calcium from 
osteoblasts and to increase renal reabsorption of calcium. PTH activity is down 
regulated by increased calcium, increased VD and possibly increased FGF-23. The 
secretion of PTH is never fully suppressed and has an extremely short half-life of ~ 4 
minutes.  
 
1.5.2 Parathyroid hormone and neurocognition 
Emerging evidence has suggested PTH may directly affect neurovascular 
integrity independent of VD homeostasis. PTH has been shown to cross the BBB and 
an exaggerated level of PTH within the CSF appears to cause neuronal degeneration 
due to cellular iCa overloading (Hirasawa et al., 2000; Khudaverdian & Chursina, 
1996). Indeed, hyperparathyroidism is the most common cause of hypercalemia. In a 
number of clinical studies, hyperparathyroidism has been reported as an independent 
risk factor of age-related cognitive decline (Bjorkman, Sorva, & Tilvis, 2008; 
Braverman et al., 2009). Furthermore, case-controlled findings show improved 
cognitive performance in some subjects with hyperparathyroidism following 
parathyroid surgery, though not all (Bollerslev, Rolighed, & Mosekilde, 2011; Coker 
et al., 2005; Walker et al., 2009). PTH has been shown to stimulate the endothelial 
expression of vascular growth factor and may play a role in endothelial dysfunction 
pathophysiology (Rashid, Bernheim, Green, & Benchetrit, 2008). Conversely, PTH 
has a purported role as a modulator of the functional activity of neurons 
(Khudaverdyan & Ter-Markosyan, 2000). Thus, it is possible that studies reporting 
detrimental effects of VDD may be a surrogate marker of PTH-induced sequelae.  
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1.6 Conclusion 
Based on experimental and clinical evidence, it is clear cerebral capillary 
integrity is pivotal to the risk and/or progression of a range a neurodegenerative 
disorders including Alzheimer’s disease. Taken together, it seems obvious to 
investigate the putative association of the highly integrated Vitamin D – Calcium - 
Parathyroid Hormone endocrinal axis and related metabolites with cerebral capillary 
vessel permeability. The study of this integrated system in terms of neuropathology 
will be exceedingly informative with regards to possible translational clinical 
interventions and may provide insight on potentially modifiable risk factors in the 
restoration/modulation of neurovascular integrity and function prior to disease 
diagnosis or progression. 
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Thesis hypothesis and specific objectives  
 
The pre-clinical studies presented in this thesis were aimed to principally 
explore the potential interactive and/or independent effects of the Vitamin D - 
Calcium - Parathyroid Hormone endocrine axis on cerebral capillary function.  A 
secondary objective was to consider in a clinical context, cognitive performance 
relative to serum Vitamin D - Calcium - Parathyroid Hormone homeostasis.  
 
 
HYPOTHESIS: The Vitamin D - Calcium - Parathyroid Hormone endocrine 
axis regulates cerebral capillary integrity and is associated with neurocognitive 
performance. 
 
 
The above hypothesis was investigated by the following objectives: 
 
 
Objective 1 
To explore the effects of hypervitaminosis D, calcium and the calcium counter-
regulatory hormone, parathyroid hormone, on the modulation of cerebral capillary 
integrity and function. Wild-type mice and rats were randomised to dietary or 
endocrinal/surgical interventions to mimic either hypervitaminosis D, hyper -or - 
hypo- parathyroid states, concomitant with altered calcium homeostasis. Groups of 
mice and rats were assigned to one of the following treatments: dietary 
supplementation of vitamin D3 ranging from 1,000 to 120,000 IU/kg of diet, 
exogenous infusion of parathyroid hormone or parathyroid tissue ablation. After 6, 
12 or 24 weeks of dietary or surgical intervention, the functional integrity of the 
BBB and neurovascular inflammation was assessed principally by three-dimensional 
immunofluorescent microscopy. Vitamin D - Calcium - Parathyroid Hormone status 
was determined by measuring serum concentrations of bioactive ionised calcium and 
parathyroid hormone.   
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Objective 2 
To investigate the putative association between Vitamin D - Calcium - Parathyroid 
Hormone homeostasis and neurocognitive performance. Serum levels of vitamin D, 
ionised calcium and parathyroid hormone, and a panel of cognitive measures 
(assessing primarily verbal episodic learning and memory) were analysed in a cross-
sectional sample of healthy middle-aged and older adults.  
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Chapter 2: Vitamin D - Calcium - Parathyroid hormone 
endocrine axis and the modulation of cerebral capillary 
integrity in rodents 
 
The content of this chapter is covered by Publication 1:  
 
Lam V., Takechi R., Pallebage-Gamarallage M., Giles C., & Mamo J. C. (2015). 
The vitamin D, ionised calcium and parathyroid hormone axis of cerebral capillary 
function: therapeutic considerations for vascular-based neurodegenerative disorders. 
Plos One, 10(4), e0125504. 
 
Synopsis: 
Background 
Cerebrovascular dysfunction characterised by the abnormal transport of 
plasma proteins into the brain parenchyme, is a common pathological hallmark of 
vascular-based neurodegenerative disorders whereby increasing clinical and 
experimental evidence suggests cerebral capillary barrier dysfunction may occur in 
the developmental/pre-clinical stages of dementia (Lorius et al., 2015; Zlokovic, 
2011). As discussed in Chapter 1, VD has received much attention in the dementia 
field due to its association with a number of neuro-beneficial properties including 
modulation of immuno-regulatory factors, neurotrophin synthesis and neuronal 
protection (Buell & Tucker, 2011; Garcion et al., 1998; McCann & Ames, 2008). 
 
Experimental evidence of whether greater VD levels and its corresponding 
metabolites are beneficial to neurovascular integrity and function is lacking. 
Moreover, the major counter-regulatory metabolites and hormones involved in VD 
homeostasis namely, calcium and PTH, have been implicated in the pathogenesis of 
neurodegenerative diseases (Bjorkman et al., 2008; Hirasawa et al., 2000; Payne et 
al., 2013; Schram et al., 2007; Tilvis et al., 2004), so synergistic and/or interactive 
effects need to be considered. Prior to the studies presented in the following 
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publication, no existing evidence had considered the endocrinal axis of Vitamin D - 
Calcium - Parathyroid Hormone in a hypervitaminosis D context in relation to 
vascular-related neurodegenerative disorders. 
 
To investigate the major components of the integrated endocrinal system and 
its association with neurovascular integrity and function, vitamin D and parathyroid 
hormone intervention studies were explored in rodent models. 
 
Methods in brief 
2 rodent species (wild-type C57BL/6J mice and Sprague-Dawley rats) were 
randomised to one of the following interventions: dietary VD supplementation across 
a normal to high dosage range, parathyroid gland ablation or infusion of exogenous 
PTH, for a duration of either 6, 12 or 24 weeks. Three-dimensional (3-D) 
immunofluorescent quantification was used to assess cerebral capillary integrity by 
measuring the parenchymal abundance of plasma protein IgG, a marker of BBB 
leakage, whereas neuro-inflammation was determined by quantification of glial 
fibrillary acidic protein (GFAP), representative of astroglial activation. Blood 
biochemistry was used to determine the calcemic status of each animal.   
 
Results in brief 
Significant cerebrovascular disturbances were seen in both experimental 
species in association with the dosage of VD supplement provided. Greater doses of 
VD were also associated with increased serum iCa and suppression of serum PTH. 
Sustained treatment effects were evident up to 24 weeks of intervention. Ablation of 
parathyroid glands increased the parenchymal abundance of IgG, concomitant with a 
reduction in serum iCa. With the provision of exogenous PTH, iCa levels increased, 
however cerebral capillary permeability of the PTH-infused animals were 
comparable to their respective controls. Both VD supplemented and PTX groups 
showed modest increases in astroglial activation, whereas PTH-infused groups 
showed a reduction in the expression of GFAP.  
 
 33	   
Discussion and conclusion in brief 
This pre-clinical study explored whether dietary induced hypervitaminosis D 
or endocrine mediated hypo - and - hyper - parathyroidism can modulate the 
permeability of the cerebral capillary layer and possibly neurovascular inflammation. 
The principal findings of these experiments demonstrate VD can significantly 
compromise cerebral capillary integrity and function, via a mechanism independent 
of calcium homeostasis. In addition, the data suggests PTH may have vasculo-
protective effects. Increased capillary permeability was not associated with 
neurovascular inflammation contrary to previous studies in rodent models where 
compromised BBB and heightened inflammation were reported (Freeman & 
Granholm, 2012; Takechi et al., 2012). 
 
Collectively, the results from this study support the role of VD in modulating 
the cerebral capillary function and permeability.  The provision of supplemental VD 
at doses that increase serum iCa and suppress serum PTH concentration compromise 
cerebrovascular integrity but do not promote neurovascular inflammation per se. The 
information gained from this highly relevant publication provides future directions to 
explore the potential mechanisms related to the modulation of the BBB in relation to 
the VD and its hormonal counterparts, particularly in the investigation of vascular-
based neurodegenerative disorders. 
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Supplementary methodology 
The following section provides detailed information on the pilot studies 
undertaken to determine the dosage range and tolerability of VD supplementation for 
the dietary intervention to model human VD status in experimental rodents. In 
addition, further details regarding parathyroid gland surgery and provision of 
exogenous PTH fragment infusion methodology are provided.  
 
Vitamin D supplementation pilot studies 
Pilot studies were undertaken to evaluate the tolerability and effects of high-
dose oral vitamin D3 supplementation administered to young wild-type C57BL/6J 
mice to mimic a state of hypervitaminosis D that is of clinical relevance. 
 
Strong evidence suggests rodents are extremely tolerant and resistant to high 
dietary VD intake across a range of concentrations (Fleet et al., 2008; Rowling, 
Gliniak, Welsh, & Fleet, 2007). The species variation is thought to be achieved by 
suppression of renal hydroxylase activity which subsequently limit the levels of its 
bioactive metabolites, regardless of the presence of high circulating 25(OH)D 
(Feldman, Pike, & Adams, 2011). Indeed, Vieth et al. (1990) reported in humans, 
free circulating 25(OH)D is 5-fold greater than in other species such as the rat 
(Vieth, Kessler, & Pritzker, 1990). Despite the low affinity of 25(OH)D for VDR, 
chronic heightened levels of the circulating pre-hormone may exceed the binding 
capacity of the VDR, override these mechanisms and cause direct gene transcription 
effects in target tissues when 25(OH)D enters the cell (Feldman, Pike, & Glorieux, 
2005; Jones, 2008; Uchida, Ozono, & Pike, 1994). Thus to achieve comparable high 
VD status in rodents, the following dietary regimen was undertaken.  
 
Each group of mice were randomly assigned to a semi-purified diet 
formulation consisting of the following vitamin D3 concentrations (IU/kg of diet): 
1,000 (control diet as per NHMRC animal care guidelines); 20,000; 40,000; 80,000 
or 120,000 (Specialty Feeds, Glenn Forrest, W.A, Australia). Calcium and 
phosphorus content was consistent for all diet formulations at 0.5% and 0.35%, 
respectively.  
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Using 3-D immunofluorescent methodology as indicated in Publication 1, the 
figure below (Figure 5) indicates the dose-response observed in terms of capillary 
permeability and dietary VD concentration. The pilot studies indicated the VD 
supplemented diets were well tolerated by the animals. 
 
 
 
 
 
Figure 5. The graphs depict a strong dose-response of dietary vitamin D3 
supplementation and parenchymal extravasation of IgG in the cerebral cortex and 
hippocampal formation in C57BL/6J mice after a 12-week dietary intervention. 
Statistical significance is represented by different letters where p<0.05 (n = 8; one-
way ANOVA followed by Tukey’s post hoc analysis).  
 
Parathyroid gland ablation 
To study the effects of clinically comparable hypocalcemia, the PTX rat 
model, a widely used endocrine model to study the biological effects of PTH 
suppression in vivo via removal of PT glands was utilized (Lempert, Scharla, Minne, 
& Ziegler, 1991). The suppression of concentrations of serum PTH and iCa are 
routinely used as surrogate markers of the removal of the PT glands (data shown in 
Publication 1).  
 
Cortex' Hippocampus'
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Exogenous parathyroid hormone infusion 
To mimic a clinically relevant model of chronic primary hyperparathyroidism 
with typical clinical manifestations such as excessive secretion of PTH and 
subsequently hypercalemia and suppressed VD status, circulating levels of PTH 
levels were increased by the controlled continual infusion of supraphysiological 
doses of exogenous PTH fragment 1-34 (Bachem Labs, Switzerland) at a constant 
rate for either 6 to 12 weeks delivered by 2ML Alzet mini osmotic pumps (Alzet, 
Durect Corporation, CA). 
 
The concentration of PTH fragment solution and more importantly the dose of 
PTH delivered per hour used to modulate circulating PTH levels were based on pioneer 
studies published by Berdud et al. (1998), summarised in Table 1 (Berdud et al., 1998). 
The calculations of pump reservoir concentrations are based on a 200g rat.  Briefly, the 
specified weight of PTH per dosage was dissolved in sterile isosmotic saline (0.9% 
sodium chloride) with 2% cysteine and adjusted to a pH of 1.4 by addition of 
hydrochloric acid. The control vehicles were filled to equivalent volumes with isosmotic 
saline and 2% cysteine. All pumps were pre-conditioned by incubation in the same 
buffer for 24 hours at 37°C prior implantation to equilibrate the flow rate of each pump. 
Thereafter, pumps were inserted within the subscapular pocket of each of the animals 
per experimental group after recovery inhalation anaesthesia.   
 
 
Dose of PTH (μg/hour/200g rat) 0.33 
Concentration of PTH solution (μg/μL) 0.13 
PTH (μg) solubilised in solution 265.60 
 
 
Table 1. Dosage of PTH fragment 1-34 to model primary hyperparathyroidism in 
Sprague-Dawley rats 
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Chapter 3: Serum 25-hydroxyvitamin D and neurocognitive 
performance 
 
 
This chapter is comprised of the following articles: 
 
 
Lam V., Albrecht M. A., Takechi R., Prasopsang P., Lee Y. P., Foster J. K., & 
Mamo J. C. L. (2016). Serum 25-hydroxyvitamin D is associated with reduced 
cognitive performance in healthy, middle-aged and older adults. European Journal of 
Nutrition, 55(4), 1503-1513. 
 
Lam V., Dhaliwal S. S., & Mamo J. C. (2013). Adjustment of ionized calcium 
concentration for serum pH is not a valid marker of calcium homeostasis: implication 
for identifying individuals at risk of calcium metabolic disorders. Annals of Clinical 
Biochemistry, 50(Pt 3), 224-229. 
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Publication 2: 
 
Lam V., Albrecht M. A., Takechi R., Prasopsang P., Lee Y. P., Foster J. K., & 
Mamo J. C. L. (2016). Serum 25-hydroxyvitamin D is associated with reduced 
cognitive performance in healthy, middle-aged and older adults. European Journal of 
Nutrition, 55(4), 1503-1513. 
 
Synopsis: 
Background 
Over the past decade, there has been a considerable amount of interest in the 
field of VD and neurocognition, with particular interest in older-aged individuals 
(Annweiler et al., 2013a; Buell et al., 2010). The majority of the literature, 
experimental and epidemiological, has been focused upon the neuro-beneficial 
properties of VD in context of correcting low VD status. Vitamin D supplementation 
has been widely promoted in the community to ‘improve’ cognition and reduce the 
risk factors of a number of chronic age-related diseases and overall mortality 
(Annweiler et al., 2015; Schottker et al., 2013). Conversely, very few studies have 
reported the effects of higher VD status and cognitive performance. Recent data from 
two large cross-sectional studies indicated cognitive impairment is more prevalent in 
individuals with higher levels of 25(OH)D, particularly those taking VD supplements 
(Granic et al., 2015b; McGrath et al., 2007). Based on these findings, it seems 
obvious VD supplementation must be addressed appropriately as further increasing 
25(OH)D levels beyond sufficient levels is associated with cognitive dysfunction.  
 
The pathophysiology associated with AD-related cognitive impairment is 
complex and involves a number of mechanisms including disruption of cerebral 
capillary integrity and function, neuro-inflammation, oxidative stress, and neuronal 
damage (Baierle et al., 2015; Ewers, Mielke, & Hampel, 2010; Keller, 2006). Indeed, 
vascular damage that causes dysfunction of the BBB can influence cognitive 
performance (Pop et al., 2013).  In context of the primary findings of Publication 1, 
where supraphysiological levels of VD were associated with compromised BBB, it 
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may be plausible to implicate higher serum VD concentration and cognitive 
impairment.  
 
The main aim of this study was to explore whether there is an association 
between individuals with ‘normal’ VD homeostasis and cognitive function. 
Moreover, the principle regulators of VD homeostasis, iCa and PTH were taken into 
consideration when exploring the putative effects of VD on cognitive performance.  
 
Methods in brief 
181 individuals between the ages of 43 to 84 (116 Females, 65 Males) were 
recruited for this cross-sectional study. Vitamin D status, determined by serum 
25(OH)D, iCa and PTH, was explored in association with cognitive assessments 
evaluating verbal episodic learning and memory via the Rey Auditory Verbal 
Learning Test (RAVLT), commonly used as the most sensitive and specific marker 
of age-related cognitive change. National Adult-Reading Test (NART), Depression, 
Anxiety and Stress Scales (DASS), age, gender, iCa and PTH were used a covariates. 
Hierarchical Bayesian modeling was used to analyse the relationship between serum 
VD homeostasis and cognitive performance.  
 
Results in brief 
Individuals with serum VD concentrations in the upper end of normal range 
were associated with poorer episodic memory performance, in particularly the trial 5 
of RAVLT and long delay free recall. Serum iCa had modest positive associations 
with certain measures of episodic memory, whereas no correlation was evident 
between PTH and any cognitive variables.  
 
Discussion and conclusion in brief 
Firstly, the findings from this study require replication in other study 
populations of larger sample size to confirm the statistical relationships identified. 
The overall results suggest higher VD status may exert negative effects on cognitive 
performance in individuals with normal Vitamin D - Calcium - PTH homeostasis. 
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Whilst the study findings require further validation, the outcomes are particularly 
important from a cognitive context, where a large body of evidence associates VD 
deficiency with age-related cognitive impairment. Despite the uncertainty of the 
optimal concentration of VD for optimal brain function and the possibility of 
‘reverse causation’, the use of VD supplements is widely promoted to ‘optimise’ 
brain/cognitive health. Overall, the administration of VD supplementation in 
individuals with adequate serum VD levels should be re-considered as the data from 
this study suggest higher VD status may not be beneficial from a cognitive 
perspective.  
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Publication 3: 
 
Lam V., Dhaliwal S. S., & Mamo J. C. (2013). Adjustment of ionized calcium 
concentration for serum pH is not a valid marker of calcium homeostasis: 
implications for identifying individuals at risk of calcium metabolic disorders. 
Annals of Clinical Biochemistry, 50(Pt 3), 224-229. 
 
Synopsis: 
Background 
Ionised calcium and PTH are important regulatory counterparts of VD 
homeostasis.  Aberrant homeostasis of both serum biomarkers have been 
individually implicated as potential risk factors of age-related cognitive impairment 
(Braverman et al., 2009; Schram et al., 2007). Based on the potential confounding 
effects of iCa and PTH on VD homeostasis and cognitive performance, both 
biomarkers were included as biological covariates for data consideration in 
Publication 2.  
 
Ionised calcium is regarded as the biologically active fraction of serum 
calcium and routinely measured via ion-electrode potentiometry (IEP) in diagnostic 
laboratories. Presently, the analysis of iCa is based on published algorithms used to 
correct for in vivo or ex vivo sampling confounders in relation to sample pH. 
However the validity and clinical relevance of reporting iCa adjusted to a pH of 7.4 
in conjunction with natural variability in serum pH remains unclear and may lead to 
inaccurate result interpretation. Based on the importance of considering serum iCa as 
a biological covariate of in the investigation of VD in relation to cognitive 
performance, the aim of this study was to investigate the validity of the algorithm 
pH-adjusted iCa value. 
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Methods in brief 
A cross-sectional sample of 285 individuals was included in the study 
analysis. Fasted blood samples were collected, handled and analysed in strict 
accordance to the International Federation of Clinical Chemistry and Laboratory 
Medicine Guidelines (Boink et al., 1992). Serum iCa and pH were measured by an 
IEP-auto analyser hosted at an accredited diagnostic laboratory. The association 
between unadjusted-iCa values, pH-adjusted iCa values and predicted-iCa values 
using a regression equation factoring in unadjusted-iCa, and serum pH were 
analysed.  
 
Results in brief 
The unadjusted-iCa concentrations and predicted-iCa values were 
comparable however adjusted-iCa values were significantly lower than unadjusted-
iCa. 15% of subject sample analyses were underestimated with hypercalemia and 
over 60% of the subjects’ calcemic status was overestimated when using the 
published algorithm.  
 
Discussion and conclusion in brief 
The findings of this study demonstrated the discordance between pH 
adjusted-iCa and unadjusted-iCa values and do not support the utilisation of 
published equations in iCa analysis and interpretation. Expressing unadjusted-iCa is 
likely to be a more valid and physiologically relevant biomarker of calcium status 
when standardised sample collection and protocols are in practice. 
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Supplementary methodology 
Additional information for Publications 2 to 5 is provided on the processes 
undertaken for the recruitment of volunteers, sample collection and finally, 
comprehensive details of each neuropsychological test component. 
 
Participant Recruitment 
Participants were recruited through a newspaper article advertised in the West 
Australian in December 2011. 312 persons registered interest and were subsequently 
screened via phone or email and excluded based on the following criteria: self-reported 
or documented malignancies, active or previous cancers, active chemotherapy, severe 
renal or gastrointestinal disease, liver dysfunction, diagnosed psychiatric disorder or 
currently taking psychotropic drugs, diagnosed memory disorder, haemophilia, head 
injury within the last 5 years, individuals with HIV and those who were unable to 
complete the neuropsychological test battery.  
 
A participant information form and consent sheet was given to all participants 
describing in detail the aim of the study, tasks expected of the volunteer and potential 
risks associated (see forms in Appendix II). Once consent was obtained, a 
comprehensive questionnaire was circulated among all participants to collect 
information on age, gender, education history, current or previous medical conditions, 
current medications/supplements, and history of head trauma. Two study visits were 
required; blood sampling and neurocognitive assessments. All participant data was 
collected between December 2011 and August 2012.  
 
Sample Collection 
A fasted blood sample was collected from each participant (approximately 5ml) 
by a trained phlebotomist for analysis of a number of serum biomarkers including 25-
hydroxyvitamin D levels, total and ionised calcium, PTH, liver function tests, kidney 
function tests, S100B, albumin, leucocyte count and C-reactive protein (specific assay 
details are provided in each individual publication). Blood samples were thereafter 
centrifuged at 3000g for 10 minutes and kept frozen at -80°C until further analysis.  
 82	   
Neuropsychological cognitive assessments 
The comprehensive panel of neuropsychological cognitive assessments 
administered to all participants was chosen on the basis on their widespread use within 
the field and ability to cover the principle domains of cognitive performance typically 
affected in age-related cognitive decline. All cognitive assessments were conducted by 
staffed trained by a registered clinical neuropsychologist. The following section 
describes in detail the test procedure for each of the measures and which cognitive 
domain is assessed.  
 
Rey Auditory and Verbal Learning Test  
The Rey Auditory and Verbal Learning Test (RAVLT) is essentially a 
neuropsychological assessment designed to evaluate verbal episodic learning and 
memory of an individual, in which the nature and severity of memory dysfunction can 
be tracked over time (Bean, 2011; Lezak, Howieson, & Loring, 2004). 
 
The RAVLT test is presented orally over five consecutive learning trials. The 
participant is read a list of 15 unrelated nouns (list A) and immediately asked to recall as 
many words as possible over five trials (T1 to T5) and referred to as short delay free 
recall (SDFR). This assesses short-term memory and incremental learning, and an 
increase in the number of words recalled per consecutive trial is expected in cognitively 
sound individuals.  Following the five trials, an interference list (list B), which is a new 
list of 15 unrelated words, is read out to the participants presented in the same manner 
where they are again asked to recall as many words as possible. Trial 6 (T6) is then 
administered immediately after recall of interference list where the participants are asked 
to recall words from list A. This essentially examines ‘working memory’ and how well 
the participant has consolidated List A to memory. Trial 7 (T7) is conducted 20 minutes 
after trial 6 and involves recall of words from the original list A without immediate prior 
exposure to the list as per previous trials, in aim to assess long-term memory (long 
delayed recall (LDFR)). Following trial 7, participants were required to complete a 
recognition trial involving the recognition of words from a list of 30 items, comprised of 
15 words from the original list A and 15 filler items. Each of the 30 words was read out 
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in random order and the participant was asked to identify whether the word was from the 
original list. Recognition memory (TR) is assessed as opposed to long delay free recall.  
 
The multiple recall trials for list A can be represented as a learning curve as seen 
in Publication 2, demonstrating relative memory capacity (Bean, 2011). Interference and 
retention is also assessed by the recall of words from list B and the immediate-recall of 
list A (Schmidt, 1996). 
 
All scores were standardised and converted to a z-score based on standard 
normative data (Schmidt, 1996). The main variables of RAVLT include: T5, T6, T7 and 
TR, which reflects short term memory, short-delay working memory, long-delay 
memory, and recognition memory, respectively. Trial 5 was used as opposed to T1 – T4 
due to saturation of results at T5. The differences between T6 and T5 (T6 - T5) and T7 
and T5 (T7 - T5) were also determined to determine a short delay forgetting score and 
long delay forgetting score, respectively. Z-scores 1.5 standard deviations below the 
mean in any of these scores were regarded as cognitively impaired in their respective 
domains.  
 
Mini-Mental State Exam 
Mini-Mental State Exam (MMSE) is a cognitive measure used to screen mental 
functioning in older adults by administering a 30-item examination over a 5 to 10 minute 
period, typically used to screen for dementia and schizophrenia (Folstein, Folstein, & 
McHugh, 1975; Schatz, 2011). A total of 30 questions consisting of 10 questions related 
to time/place orientation, 3 questions for registration – object memory, 5 questions 
related to attention and calculation, 3 questions for short-term recall and 9 questions 
related to language and such as naming of objects, repetition of words, comprehension, 
reading and writing. Thus, the MMSE covers a variety of cognitive domains and 
generally used a screening tool rather than specific domain measure (Molley & Standish, 
1997). A test score of less than 23 correctly answered questions is clinically interpreted 
as mental impairment, although the sensitivity of MMSE scoring remains controversial 
due to the variability of age and education (Crum, Anthony, Bassett, & Folstein, 1993).  
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Depression, Anxiety and Stress Scale  
The Depression, Anxiety and Stress Scale (DASS) is a 21-item self-report 
instrument designed to measure current negative emotional states of depression, anxiety 
(symptoms of psychological arousal) and stress (enhanced cognitive and subjective 
symptoms of anxiety). These scales are merely a quantitative measure of distress in 
relation to depression, anxiety and stress, and not independently used for clinical 
diagnosis. High scores reported on the DASS is indicative of a high level of distress in 
the individual and were taken into consideration.  
 
National Adult Reading Test  
The National Adult Reading Test (NART) is an untimed test that assesses the 
ability of an individual to correctly read and pronounce 30 unrelated words and utilised 
as a means of assessing general intelligence to adjust for potential confounders from the 
other cognitive test components. The scores from the test evaluate premorbid levels of 
intellectual functioning (Nelson & Willison, 1991). 
 
Digit Span Test  
The Digit Span tests are a set of verbal subtests derived from the Wechsler Adult 
Intelligence Scale version 3 (WAIS-III) used to primarily assess an individual’s working 
memory, mental capacity, attention and their ability to retain a circumscribed amount of 
information for a short period of time (Wechsler & Scale, 1997). 
 
A random sequence of numbers was read to the participant for the digit span 
forward assessment. Thereafter, the participant was asked to recall the numbers in the 
exact order they were presented, assessing short-term memory (forward digit span). 
Following this, the participant is asked to attempt to recall a set numbers in reverse 
order, which accounts for both short-term and working memory (backward digit span). 
The raw score of the test is the sum of the trials completed correctly and thereafter 
converted to an age-corrected scale score where particular cut-off scores are used for 
screening various types of cognitive impairments (Wambach et al., 2011).  
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Digit Symbol Coding 
The Digit Symbol Coding test is a timed performance subtest derived from the 
WAIS-III that evaluates an individual’s perpetual speed and memory by completing a 
coding task, which involves the transcription of a geometric symbol with its 
corresponding numerical digit (Bettcher, Libon, Kaplan, Swenson, & Penney, 2011; Joy, 
Kaplan, & Fein, 2004). The score attained is the number of correctly transcribed items in 
the prescribed time limit and is sensitive to age-related changes, dementia and brain 
damage (Glosser, Butters, & Kaplan, 1977; Joy, Fein, Kaplan, & Freedman, 2001; 
Kluger et al., 1997). 
 
Stroop Test 
The Stroop test is used for the assessment of selective attention and executive 
function of individuals (Sbordone, Saul, & Purisch, 2007). The Victorian version of the 
Stroop test used is a shortened version of the original Stroop task. Stroop Colour and 
Word tests is comprised of a series of 3 test papers that consists of the following (1) 
Dots - the participants were asked to simply identify the colour of each dot on the page 
(red, green, yellow or blue) for each row from left to right; (2) Words – participants were 
required to name the ink colours in which colour words are printed and to disregard their 
verbal content; (3) Colours – participants were subjected to an interference effect where 
non-corresponding coloured stimuli and colour names were presented, requiring the 
participant to name the colours in the task as requested (Strauss, Sherman, & Spreen, 
2006). A cognitively impaired individual would respond slower and demonstrate 
difficulties in the completion of each of the tasks (Koss, Ober, Delis, & Friedland, 1984; 
Ponsford & Kinsella, 1992). 
 
Delis-Kaplan Executive Function System and Boston Naming Test 
The Delis-Kaplan Execute Function System (D-KEFS) and the 60-item Boston 
Naming Test (BNT) were used to assess verbal ability of the study cohort. Deficits in 
verbal fluency ability is found associated in patients with mild-cognitive impairment 
(MCI) and AD when compared to age-matched controls (Nutter-Upham et al., 2008; 
Randolph, Braun, Goldberg, & Chase, 1993). 
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D-KEFS is a battery of psychometric tests used to assess a wide array of higher-
level executive functions such as ‘cognitive flexibility, ability to problem-solve, 
conceptual reasoning, inhibition, multi-tasking and non-verbal and verbal creativity’ 
(Fine & Delis, 2011). D-KEFS verbal fluency, category fluency and switching tests were 
used in our modified test battery to assess primarily for milder forms of dementia-related 
cognitive deficits. 
 
The D-KEFS subtest evaluates the fluent productivity of the verbal domain. The 
participant is requested to say words beginning with a letter specified by the examiner, 
present words that belong to a specific semantic category and alternate between saying 
words from two different semantic categories, which ultimately assesses letter fluency, 
category fluency and categorical switching, respectively. Raw scores derived from each 
of the subtests are converted to age-scaled scores. 
  
The 60-item BNT is a confrontation naming-assessment where the participant is 
shown 60 line-drawn pictures and asked to name each item (Mitrushina, Boone, Razani, 
& D'Elia, 2005). If the participant misperceives the picture, an appropriate semantic cue 
is given. If more than 20 seconds was required to name an item, a standard phonemic 
cue was given. The number of correct responses scores the test. 
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Chapter 4: Serum S100B and neurocognitive performance 
 
The following article covers the content of this chapter: 
 
Lam V., Albrecht M. A., Takechi R., Giles C., James A. P., Foster J. K., & Mamo J. 
C. (2013). The serum concentration of the calcium-binding S100B is positively 
associated with cognitive performance in older adults. Frontiers in Aging 
Neuroscience, 5, 61.  
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Publication 4: 	  
Lam V., Albrecht M. A., Takechi R., Giles C., James A. P., Foster J. K., & Mamo J. 
C. (2013). The serum concentration of the calcium-binding S100B is positively 
associated with cognitive performance in older adults. Frontiers in Aging 
Neuroscience, 5, 61.  
 
Synopsis: 
Background 
S100B is a low-molecular weight (21kDa) calcium-binding, neurotrophic 
protein produced predominantly by astroglial cells. Typically regarded as a CNS-
specific protein, S100B is typically present in low concentrations in the systemic 
circulation when compared to CSF-S100B levels (Grocott & Arrowsmith, 2001; 
Reiber, 2001). Experimental and clinical data show serum S100B levels are 
markedly increased after head trauma/brain injury, commensurate with increased 
permeability of cerebral capillary endothelium (Kapural et al., 2002; Marchi et al., 
2003). Individuals with mild traumatic injury are often cognitively impaired post-
insult where changes in memory recall, attention, executive functioning and 
behavioural changes are reported (Smith, Johnson, & Stewart, 2013; Williams, 
2013). Therefore, the aim of this study was to investigate the association between 
serum S100B, a putative marker of cerebral capillary dysfunction, and 
neurocognitive function.  
 
Methods in brief 
A cohort of 219 participants were included in this study where serum 100B 
was measured and considered against a comprehensive neurocognitive test battery 
including: MMSE, RAVLT, Delis-Kaplan Executive Function System (D-KEFS) 
verbal fluency subsets, Boston Naming Test (BNT), NART, Digit Span and Digit-
Symbol Coding subtests from the Wechsler Adult Intelligence Scale (WAIS-III), and 
the Stroop test. A nested domain Bayesian mixed-model was used to analyse the 
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relationship between S100B and cognitive performance, where age, gender and 
NART were used as covariates. 
 
Results in brief 
No participant had serum S100B concentrations indicative of head trauma or 
injury. Serum S100B was found to positively correlate across all cognitive domains, 
in particular perpetual speed, Stroop test and verbal fluency.  
 
Discussion and conclusion in brief 
Overall, the results from this study demonstrate that serum S100B is positively 
associated with better global cognitive performance in healthy older adults. As the 
study cohort was functioning within ‘healthy’ range and no CNS dysfunction was 
reported, the findings are supportive of S100B’s neurotrophic effects and pro-oxidant 
properties.  
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Chapter 5: Serum albumin and neurocognitive 
performance 
 
The following article covers the content of this chapter: 
 
Lam V., Albrecht M. A., Takechi R., Heidari-Nejad S., Foster J. K., & Mamo J.C. 
(2014). Neuropsychological performance is positively associated with plasma 
albumin in healthy adults. Neuropsychobiology, 69(1), 31-38. 
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Publication 5: 
 
Lam V., Albrecht M. A., Takechi R., Heidari-Nejad S., Foster J. K., & Mamo J. C. 
(2014). Neuropsychological performance is positively associated with plasma 
albumin in healthy adults. Neuropsychobiology, 69(1), 31-38. 
 
Synopsis: 
Background 
Albumin is a major plasma protein important in a number of physiological 
functions including regulation of peripheral microvascular permeability, 
inflammation, oncotic pressure, and oxidant status (Burtis & Ashwood, 2001; 
Demling, 1986; Oettl & Stauber, 2007). Approximately 42% of total albumin is 
found plasma and the remaining fraction is found in extravascular compartments. 
Reduced concentrations of plasma albumin are related to an increase in vascular 
permeability, which results in the leakage of proteins, inflammatory mediators and 
large volume of extracellular fluid into interstitial space (Fleck et al., 1985; 
Nicholson, Wolmarans, & Park, 2000). Moreover, protective effects of albumin on 
capillary integrity were demonstrated by the prevention of apoptosis of cultured 
endothelial cells (Zoellner et al., 1996). Low levels of plasma albumin due to altered 
distribution between intra - and - extra -vascular compartments or reduced 
reabsorption relative to kidney dysfunction, have been associated with critical illness, 
increased morbidity and mortality, and poorer mental health (Goldwasser & 
Feldman, 1997; Nicholson et al., 2000; Spiegel & Breyer, 1994). Based on its 
important physiological functions, circulating plasma albumin may be related with 
cognitive performance. Indeed, positive associations between plasma albumin and 
cognitive performance have been reported, however these findings are generally 
derived from subjects with impaired albumin homeostasis due to liver or renal 
dysfunction (Griva et al., 2004; Ortiz et al., 2006). The aim of this study was to 
determine whether an association exists between plasma albumin and global 
cognitive performance in a cohort of healthy adults free of liver or renal dysfunction.  
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Methods in brief 
A wide-range neuropsychological test battery was used to explore the 
relationship between global cognitive performance and plasma albumin homeostasis 
in 222 healthy participants between the ages of 43 and 84, free of liver or renal 
impairment. A nested-domain Bayesian mixed-model approach was used to analyse 
the data, where age, gender and acute-phase proteins, were used a covariates.  
 
Results in brief 
Serum albumin was positively correlated with better performance across a 
range of cognitive domains range assessed by our comprehensive test battery. 
Measurement of perceptual speed, Stroop and verbal ability domains showed the 
greatest positive association with plasma albumin.  
 
Discussion and conclusion in brief 
Our findings extend the findings of previous studies conducted in hypo-
albuminaemic individuals and to our knowledge, present for the first time, a positive 
association between plasma albumin homeostasis and global cognitive performance 
in a cohort of healthy individuals with normal renal and liver function. The 
relationship reported between albumin and cognitive function suggests cognitive 
decline may result from a state of heightened inflammation due to compromised 
vascular permeability mediated by plasma albumin.   
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Chapter 6: General discussion, limitations and future 
directions 
 
The final chapter of this thesis includes a general discussion to deliberate the 
major results reported in the animal model studies presented in Chapter 2 and the 
cross-sectional clinical study presented in Chapter 3. This chapter discusses potential 
mechanisms and significance of the findings in which VD and its homeostatic 
counterparts may modulate cerebral capillary integrity and in a clinical context, the 
potential effects of VD on neurocognitive function. In addition, the limitations 
relevant to each of the studies presented as part of this thesis are addressed followed 
by the consideration of future study directions.  
 
6.1 General discussion 
The fundamental findings of Chapter 2 and Chapter 3 support the broad thesis 
hypothesis that the ‘Vitamin D - Calcium - Parathyroid Hormone’ endocrinal axis 
has vascular-modulating effects on cerebral capillary integrity. The key results 
derived from the in vivo animal model studies demonstrated for the first time the 
potential detrimental effects of hypervitaminosis D on cerebral capillary integrity. 
Experimental and clinical evidence suggests compromised integrity of the cerebral 
capillary endothelium precedes cognitive impairment and the onset of AD and VaD, 
however the potential effects of BBB dysfunction on cognitive performance remain 
poorly understood (Bell & Zlokovic, 2009; Ujiie, Dickstein, Carlow, & Jefferies, 
2003). The second principal finding presented was the observation that verbal 
episodic memory performance was negatively associated with serum VD 
homeostasis in otherwise healthy, older aged adults. The findings were considered in 
the context of iCa and PTH homeostasis and in a broader context are consistent with 
the notion that this may occur via modulation of cerebral capillary function. The 
overall findings suggest that clinically, supplementary use of VD should only be 
considered if there evidence of VD deficiency.   
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6.1.1 Cerebral capillary dysfunction and cognitive performance in 
late-onset Alzheimer’s disease and vascular dementia 
The cerebral capillary endothelium representing the main interface between 
the systemic circulation and brain parenchyme is crucial in maintaining CNS 
homeostasis (Banks, 2012; Saunders, Ek, Habgood, & Dziegielewska, 2008). 
Cerebral capillary dysfunction is characterised by morphological changes in capillary 
structure and proliferative changes in smooth muscle cells which are pseudo-
pathologies often reported in a number of neurodegenerative diseases including AD, 
VaD, Parkinson disease and multiple sclerosis (Chung et al., 2010; Nicolakakis & 
Hamel, 2011; Tourdias & Dousset, 2013; Zlokovic, 2008). Loss of BBB 
functionality may result in the ‘leakage’ of peripherally-derived neurotoxic 
substances into the CNS; deranged protein-transporter systems leading to inadequate 
nutrient supply; a potential accumulation of neurotoxic substances in the CNS and 
entry of inflammatory compounds that are normally excluded (Erickson & Banks, 
2013; Serlin, Levy, & Shalev, 2011). A consequence of these perturbations include 
altered protein expression and secretions of cytokines and vasoactive substances by 
endothelial cells and cells of the neurovascular unit that can initiate an inflammatory 
cascade, promote oxidative stress and exacerbate neuronal damage (Erickson & 
Banks, 2013; Serlin et al., 2011). 
 
Accumulating evidence suggests compromised integrity of the cerebral 
capillary endothelium may precede amyloidosis and neurodegeneration (Grammas, 
2011). A number of animal model studies have reported progressive behavioural and 
cognitive changes, hippocampal and cortical atrophy, and neuronal dysfunction, as a 
result of prolonged cerebral capillary dysfunction (Bell et al., 2010; Bell et al., 2012; 
Grammas, 2011; Winkler et al., 2014). Consistent with a causal role, pathological 
alterations of the BBB coincide with progressive decline of cognitive performance 
(Frisoni, Galluzzi, Pantoni, & Filippi, 2007; Popescu et al., 2009) and extensive 
capillary damage has been reported in brain regions specifically involved in 
cognition (Hosokawa & Ueno, 1999; Montagne et al., 2015). Indeed, a progressive 
increase in cerebral capillary permeability may precede hippocampal atrophy as 
demonstrated in older-aged mildly cognitively impaired and AD-individuals 
(Apostolova et al., 2010; Montagne et al., 2015; Whitwell et al., 2012). Both 
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experimental and clinical data have suggested that the progression of AD may be 
halted upon restoration of cerebrovascular function through dietary and/or 
pharmacological interventions (Dickstein et al., 2006; Gorelick et al., 2011; Takechi 
et al., 2014; Takeda et al., 2009). 
 
6.1.2 Vitamin D - Calcium - Parathyroid hormone homeostasis and 
cerebral capillary permeability and neurocognitive performance 
 
6.1.2.1 Putative effects of vitamin D on cerebral capillary 
endothelia and neurocognitive performance  
The extra-skeletal roles of VD, particularly in neurocognitive performance, 
have been an area of considerable interest in recent years (McCann & Ames, 2008). 
The major components of the VD system, the VD receptor and its key activation 
enzymes, have been identified in brain regions commonly affected in 
neurodegenerative diseases (Eyles et al., 2013; Eyles et al., 2005; Fernandes de 
Abreu, Eyles, & Feron, 2009). As discussed in Chapter 1, the vast majority of the 
VD literature relative to its neuroprotective properties has been studied extensively 
in context of VD deficiency. A number of experimental studies have reported an 
association between VD deficient rodent models and modulation of specific brain 
biomarkers, glucose metabolism, brain protein expression and behavioural changes 
(Almeras et al., 2007; Altemus, Finger, Wolf, & Birge, 1987; Durk et al., 2014; 
Feron et al., 2005; Groves et al., 2013; Keeney et al., 2013b). A number of cross-
sectional and epidemiological studies have defined a positive association between 
serum VD concentration and better cognitive performance (Littlejohns et al., 2014). 
Upon correction of VD deficient status, both experimental and clinical studies have 
reported attenuation of various brain biochemical stressors and improvement in 
behavioural/cognitive performance (Latimer et al., 2014; Przybelski & Binkley, 
2007; Wang et al., 2001). Contrasting data found no marked differences in 
experimental models of VD deficiency and their relevant controls (Brouwer-Brolsma 
et al., 2014; Byrne et al., 2013). Different experimental design including dietary 
composition and concentrations of VD among the studies may have led to 
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inconsistent results among the literature. In addition, gradual modification of dietary 
VD consumption rather than abrupt changes in VD content would closely represent a 
better, physiologically relevant model.  
 
Brown et al. (2003) showed paradoxical results in which VD treatment of 
cultured hippocampal cells led to significant cellular apoptosis (Brown, Bianco, 
McGrath, & Eyles, 2003). Apoptotic effects of high levels of VD were also 
demonstrated in studies in cancerous prostate and breast cell lines (Johnson, 
Hershberger, & Trump, 2002; Narvaez, Zinser, & Welsh, 2001). Parallel to the 
findings of Brown and colleagues (2003), Granic et al. (2015) and others have 
demonstrated a biphasic relationship between VD status and global cognition in the 
elderly in which both low and high VD status impose adverse effects on the CNS 
(Brown et al., 2003; Granic et al., 2015b; McGrath et al., 2007). Clearly, there is a 
paucity of studies investigating the adverse effects of VD in an excess context and 
the potential mechanisms underlying the physiological effects of VD in the CNS 
warrant further investigation. 
 
The results presented in Chapter 2 and Chapter 3 highlight the importance of 
considering the adverse effects of hypervitaminosis D in association with the CNS. 
Central to the thesis hypothesis, Chapter 2 introduced for the first time, the causal 
role of VD in modulating the permeability of the BBB in context of dietary-induced 
hypervitaminosis D. Marked disturbances in barrier properties of cerebral capillary 
vessels associated with exogenous supplementation of dietary VD was demonstrated 
in 2 rodent species, concomitant to serum hypercalcemia and suppression of 
circulating PTH. The mechanisms underlying hypervitaminosis D-mediated cerebral 
capillary dysfunction are unclear. Durk and colleagues recently identified abundant 
VDR expression on rat and mouse brain capillary endothelia in both in vivo and in 
vitro studies (Chow, Sondervan, Jin, Groothuis, & Pang, 2011; Durk et al., 2012; 
Durk et al., 2015). Moreover, activation of neural VDR by administration of its 
bioactive ligand was found to alter the pharmacokinetics of endothelial p-
glycoprotein expression and its substrates (Durk et al., 2015). Whilst these findings 
do not directly implicate VD and the regulation of cerebral capillary function and 
permeability, they certainly support this notion relative to the study findings. In 
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addition, increased transcytosis of plasma proteins into the brain parenchyme may be 
due to upstream effects of VD on intracellular calcium homeostasis as seen in 
neuronal ageing (Alexianu, Robbins, Carswell, & Appel, 1998; Gascon-Barré et al., 
1994). Indeed, pericyte and astrocytic function may be modulated based on calcium 
regulatory mechanisms and further influence capillary permeability (Abbott et al., 
2006; Hughes et al., 2006; Peppiatt, Howarth, Mobbs, & Attwell, 2006).  
 
Interestingly, the results from Chapter 2 do not suggest that exaggerated 
provision of supplemental VD significantly promote neurovascular inflammation per 
se. Substantive neuro-inflammation commonly co-exists with compromised cerebral 
capillary endothelium induced by diets enriched in pro-atherogenic lipids (Freeman 
& Granholm, 2012; Grammas, 2011; Takechi et al., 2012). The immuno-modulating 
properties of VD have been well documented and in vitro studies have demonstrated 
direct effects of VD in modulating pro-inflammatory cytokine production in the 
brain (Lefebvre, Montero-Menei, Bernard, & Couez, 2003; Moore et al., 2005).  
Whilst the experimental design does not investigate if VD will attenuate 
neurovascular inflammation per se, it is possible the pro-inflammatory nature of the 
vitamin may have modulated the degree of neuro-inflammation in relation to 
dysfunction of cerebral capillary vessels.  
 
Based on the experimental findings of Chapter 2, Chapter 3 extends on the 
putative regulatory properties of VD influencing cognition. Cross-sectional data from 
a group of healthy middle aged to older aged individuals demonstrated that greater 
serum VD status was associated with poorer verbal episodic memory, a sensitive and 
specific marker of age-related cognitive changes. Indeed, a multitude of factors are 
involved in cognitive performance however as previously discussed, compromised 
cerebral capillary endothelium is considered a major determinant of declined 
cognitive performance. The findings from this study are in concert with those of 
Granic et al. (2015) and McGrath et al. (2007); higher serum VD concentrations 
coincide with decline in global cognitive performance (Granic et al., 2015b; 
McGrath et al., 2007). Moreover, the positive effects of VD on brain development 
and cognition as postulated by Annweiler et al. (2009) and others are not supported 
by a number of studies (Annweiler et al., 2009; Dean et al., 2011; Michos et al., 
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2014; Schneider et al., 2014). It remains unclear whether the neuroprotective actions 
of VD are active only in VD deficient individuals or if it exerts specific 
pharmacological effects in those with adequate concentrations of VD. 
 
6.1.2.2 Putative calcium-related implications of dysfunctional 
blood-brain barrier and cognitive function 
Vitamin D is a potent regulator of extracellular and intracellular calcium 
homeostasis. Cellular control of calcium homeostasis supports brain physiology and 
the maintenance of cognitive health. Complex integrative mechanisms of 
intracellular calcium signalling regulate neuronal plasticity underlying learning and 
memory and neuronal survival (Zündorf & Reiser, 2011).  
 
In Chapter 2, elevated serum iCa markedly correlated with substantial 
increases of cerebral capillary permeability in VD supplemented rats and mice. In 
contrast, mildly increased BBB permeability concomitant to reduced serum iCa was 
reported in the PTX rat model whereas exogenous administration of PTH fragment 
did not increase capillary permeability despite a considerable increase in serum iCa. 
These findings suggest deranged calcium regulation is unlikely the causative factor 
in the breakdown of capillary endothelium but may exacerbate cellular 
dysfunctioning via promotion of neurotoxic signalling cascades.   
 
In neurodegenerative disorders such as AD, neuronal calcium-regulating 
systems are compromised (Foster, 2006). Talmor-Barkan et al. (2009) demonstrated 
hypocalcemia exacerbated vascular endothelial cell inflammation and thereby 
cellular function (Talmor-Barkan et al., 2009b). Recent in vivo studies by Hopp et al. 
(2015) reported chronic neuro-inflammation and neuronal calcium dysregulation 
synergistically modulate memory deficits and synaptic dysfunction (Hopp et al., 
2015). Although not investigated in this study, loss of calcium-phosphate regulatory 
mechanisms may cause vascular calcification of the capillary endothelia and 
exacerbate the loss of BBB functionality. Indeed, Payne and colleagues have 
published reports on exaggerated serum iCa in association with cerebral white matter 
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lesions, greater brain lesion volumes and initiation of the apoptotic cascade (Payne et 
al., 2008; Payne et al., 2014). 
Vitamin D has been reported to modulate intra-neuronal calcium homeostasis 
by controlling voltage-gated calcium channels (Annweiler et al., 2010; Garcion, 
Wion-Barbot, Monetero-Menei, Berger, & Wion, 2002). Higher serum iCa (upper 
end of normal range) levels was found correlated with better cognitive performance 
in Chapter 3. These results are in disagreement with the findings of Schram et al. 
(2007) and others who reported greater cognitive decline in older adults with higher 
serum iCa concentrations (Schram et al., 2007; Tilvis et al., 2004; van Vliet et al., 
2009). It is possible calcium may exert a protective effect on cognitive function 
through its feedback regulation of VD homeostasis.  
 
6.1.2.3 Potential neurovascular-beneficial effects of parathyroid 
hormone 
Emerging evidence has implicated PTH in directly affecting neurovascular 
integrity independent of VD homeostasis. Significant association between serum 
concentrations of PTH and cerebral capillary integrity was reported in Chapter 2. In 
both intervention models of VD supplementation and parathyroid gland-ablation 
where serum levels of PTH were markedly suppressed, a direct neurovascular 
protective effect was purported. However these effects should not be considered 
alone as VD and PTH act as regulatory counterparts of one another. Indeed, many 
cases of hyperparathyroidism arise from VD deficiency. In vitro studies report that 
endothelial cells abundantly express PTH-receptor 1 and that PTH stimulates the 
modulation of endothelial cell proliferation by promoting the expression of vascular 
endothelial growth factor (VEGF) (Rashid, Bernheim, Green, & Benchetrit, 2007; 
Rashid et al., 2008; Throckmorton et al., 2002). Moreover, PTH has been implicated 
as a modulator of the functional activity of neurons (Khudaverdyan & Ter-
Markosyan, 2000). Conversely, Hirasawa et al. (2000) demonstrated exaggerated 
concentrations of CSF-PTH led to cellular-iCa overload and consequently, neuronal 
cell death (Hirasawa et al., 2000).  
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Clinical primary hyperparathyroidism has been implicated as a primary risk 
factor of age-related cognitive deterioration and cognitive performance was found to 
improve upon correcting the cause of excessive PTH synthesis and secretion 
(Bjorkman et al., 2008; Roman et al., 2005). Serum PTH levels were not correlated 
with better cognitive performance in Chapter 3 and thus not assimilated to the 
findings of Chapter 2. Due to the nature of our study cohort with relatively normal 
VD - iCa - PTH homeostasis, the association between cognitive performance and 
serum PTH must not be excluded on this basis.  
 
6.1.2.4 Conclusion 
Cerebral capillary dysfunction is frequently observed in neurodegenerative 
disorders including AD and VaD. Reduced functionality of the BBB is associated 
with neuro-inflammatory changes that ultimately cause tissue damage and negatively 
impact specific domains of neurocognition. Indeed, increasing dementia research is 
focused upon vascular-related implications in delaying disease development and 
clinical progression. 
 
As with all vitamin and nutrients, the complex interplay of many factors may 
contribute to hypervitaminosis D and compromised cerebral capillary permeability 
and neurocognitive performance. The major findings presented in this thesis provide 
an important platform in understanding potential mechanisms and possible treatment 
of AD/VaD relative to VD homeostasis and its hormonal counterparts. The main 
outcomes of this thesis were that hypervitaminosis D causes cerebral capillary 
aberrations in genetically un-manipulated rodents that may be associated with poorer 
cognitive performance. The findings reinforce the importance of establishing an 
optimal concentration for serum VD, particularly in older aged adults, as higher 
concentrations of VD are potentially detrimental. Thus based on the findings from 
the studies presented, the administration of VD supplementation should be 
considered with caution based on the paradoxical damaging effects that can occur 
when orally ingested in high doses. Further studies are required to elucidate the 
specific mechanisms involved in VD homeostasis and cerebral capillary dysfunction 
and cognitive performance.  
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6.2 Limitations of the present study 
The genetically un-manipulated mouse and rats models used in this study are 
commonly used rodent models in the context of VD experimental research including 
dietary interventions and behavioural/cognitive studies.  Whilst the distribution of 
the VD receptor and its regulatory enzyme, 1,α-hydroxylase, are closely distributed 
in the human and rodent adult brain, studies have indicated species differences in VD 
metabolism and the binding kinetics of 25(OH)D to VD binding protein (Eyles et al., 
2005; Luine, Sonnenberg, & Christakos, 1987; McCann & Ames, 2008; Vieth et al., 
1990). A limitation of the animal model studies was the requirement to dose rodent 
models with substantially greater VD dosage than what occurs in a clinical context. 
Thus the translation of study findings from animal to clinical studies must be 
carefully considered. Cognitive assessment was also not considered appropriate in 
the animal model studies because of confounders in extrapolation to human cognitive 
performance measures. The young age of rodents following dietary/surgical 
intervention and the uncertainty as to whether rodent cognitive measures truly assess 
behaviour, learning or explicit memory would limit consideration of whether 
hypervitaminosis D compromises cognitive performance as a consequence of 
cerebral capillary dysfunction.  
 
The parenchymal abundance of plasma protein IgG was used as a surrogate 
marker of cerebral capillary permeability and GFAP was used to measure the extent 
of neurovascular inflammation/astroglial activation. As the semi-quantitative 
measurement of IgG extravasation is indicative only of cerebral capillary 
dysfunction, the microstructure of the capillary endothelia and astroglial end-feet 
should be further investigated to corroborate the study findings. Additionally, further 
exploration of the structural features of the neurovascular unit may be insightful.  
 
The findings from the clinical study are valuable in context of the expanding 
VD research in the dementia field. The primary limitation of this study is that 
presently, there is no sensitive marker of cerebral capillary function (permeability) 
that can be readily measured and thus the results cannot be directly correlated with 
cognitive performance of the study population. A larger sample size and a 
longitudinal study design would be more informative in terms of blood sampling and 
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cognitive measurements. However, single samples and similar cross-sectional study 
designs have been reported previously (Buell et al., 2010; McGrath et al., 2007). As 
our cross-sectional cohort sample consisted of subjects free of major psychiatric 
illness and cognitive impairment, our findings may not truly represent general 
clinical populations at risk of cognitive decline or who already exhibit mild cognitive 
impairment, diagnosed memory or emotional disorders.   
 
6.3 Future directions and clinical implications 
The principle and novel findings presented in this thesis suggest a causal role 
of hypervitaminosis D and its hormonal counterparts in the modulation of cerebral 
capillary permeability and in a clinical context, poorer cognitive performance. The 
data derived from the integrated studies suggest that the use of supplementary VD 
should only be considered in context of VD deficiency. It is crucial the critical 
regulatory effects of VD on cerebral capillary structure and function are further 
investigated as this may enable the recommendation for the use of VD supplements 
in the context of cerebrovascular integrity. 
 
The effects of VD and its metabolite concentrations vary among individuals 
based on the genetic variation of the VD receptor, which has been implicated with 
susceptibility of age-related changes in cognitive function and depressive symptoms 
in the elderly (Kuningas et al., 2009). The measurement of the pro-hormone, 25-
hydroxyvitamin D (25(OH)D) is universally accepted as the marker of vitamin D 
status due to its bioavailability and stable half-life when compared to its’ active 
metabolites. However, whilst circulating levels of the prohormone may reflect a 
longer half-life, it does not represent the circulating levels of the physiologically 
relevant vitamin, calcitriol, responsible for transcription of the genomic and non-
genomic actions of VD. Indeed, may be marker of poor health (reverse causation) 
rather than a risk factor of adverse cognitive outcomes. Further studies need to 
identify and validate the most suitable VD ‘analyte’ in a neurocognitive context to 
allow for recommendations of ‘optimal’ VD concentrations.  
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 To further expand on the findings from the animal studies, trans-endothelial 
blood-to-brain protein kinetics need to be considered in detail to determine the 
mechanisms underlying VD-mediated BBB dysfunction. From a translational 
perspective, randomised controlled clinical trials involving VD and cognition are 
lacking in the literature and warrants further investigation. Findings from randomised 
controlled trials may provide valuable insight on the paradoxical mechanisms of VD 
involved in cognitive performance and contribute to development of treatment 
strategies.  
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